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Abstract:
Folylpoly-γ-glutamate

synthetase

(FPGS)

catalyzes

the

formation

of

polyglutamate forms of the reduced folates and antifolates such as methotrexate (MTX)
and pemetrexed; this allows the retention of folates and antifolate cancer drugs inside
the cell. The enzyme activity of FPGS is essential for cell proliferation and survival.
The mouse fpgs gene contains two promoters spaced 10 kb apart which are activated in
a tissue-specific manner. The upstream promoter (P1) and exons A1a and A1b are used
in some differentiated tissues, mainly liver and kidney, whereas the downstream
promoter (P2) and exon 1 are used in rapidly dividing cells. In contrast, the human fpgs
gene expresses virtually all transcripts from the downstream promoter. In order to more
faithfully mimic human folate metabolism in the mouse, we have deleted the upstream
promoter and the associated two small exons of fpgs in the mouse genome by
homologous recombination.

Homozygous deletion mice survive embryonic

development, grow to adulthood, and reproduce through several generations, they
appear to be normal. The results of Q-RT-PCR analysis on RNA from adult mouse liver
of three different genotypes (A1aA1b +/+, +/-, -/-) indicated that deletion of P1 results
in the release of promoter interference of P2, and activation of the downstream P2
promoter is increased by 3-5 fold. Interestingly, the total FPGS mRNA expression in
KO mouse liver is 20-100 fold lower than in liver from wild-type mice. However when
the FPGS activity was measured using an FPGS enzyme assay, the liver of knockout
mice appeared to have only 2 fold lower enzyme activity than liver from wild-type mice.
In conclusion, we have successfully generated a mouse which reflects human folate

xi

metabolism much closer than seen in wild type mice. The FPGS- humanized mouse
liver model would be an appropriate in vivo tool for the study of the antifolate drug
toxicity and inhibition.
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Chapter 1: Introduction

Folate Metabolism
Folate is the generic term for all chemical derivatives with the biological activity of
folic acid. It is water soluble B vitamin that naturally occurs in meat, dark leafy
vegetables, and some fruits, and exists as various reduced forms of folate with one or
more glutamate moieties. Mammals do not have the ability to synthesize folates de novo
as do prokaryotes and plants, and thus all mammalian species require preformed folates
in their diet. Most dietary folates are polyglutamated and reduced derivatives, and are
hydrolyzed to monoglutamate forms by ɤ-glutamylhydrolase (GH) in the gut prior to
absorption across the intestinal mucosa. After crossing the mucosal cell barrier the
folates are released into the portal circulation. 5-methyl-tetrahydrofolatemonoglutamate
(5-CH3-H4PteGlu) is the major form of folate in plasma and is loosely associated with
plasma albumin in circulation. Most of the monoglutamate folate is then taken up by
the liver, where it is metabolized to polyglutamated derivatives by folypolyglutamate
synthase (FPGS) and retained or released into blood and bile (Bailey, 1994, Selhub,
1983). Folate monoglutamates are hydrophilic, bivalent anions present in serum at tens
of nanomolar (nM) concentrations. There are three folate transport systems used for
cellular transport of folate into the cells; 1.) The folate binding proteins or folate
receptors (FRα,β,ɤ). These are membrane-bound receptors that mediated the
unidirectional transport of folate into the cell. These receptors have high binding
affinity for folic acid and 5- CH3-H4PteGlu. Previous studies have shown that
internalization of the monoglutamate form of folate bound to the folate receptor is
through receptor-mediated endocytosis (Antony, 1992. 1996). 2.) Reduced folates and
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most antifolates can be transported by the reduced folate carrier (hRFC1, SLC19A1),
which is a bidirectional anionic exchanger with high affinity for reduced folates
(Sirotnak, 1999). The RFC is involved in intestinal and renal folate absorption. The
RFC-mediated uptake of reduced folates is coupled with efflux of cytoplasmic organic
phosphate (adenine nucleotide and thiamine mono- or pyrophosphate) (Zhao, 2001). 3.)
The proton-coupled folate transporter (PCFT/SLC46A1) is another route of folate
uptake, which has high affinity for both folic acid and reduced folates and functions
optimally at acidic pH. This is a unidirectional transport route of folates into the cell and
is mediated by a protein mainly expressed in the apical membrane of the intestine and
other epithelial cells (Subramanian et al, 2008). At the cellular level, the uptake of
folates mainly depends on FR, RFC and PCFT transporters (Fig. 1). Folate efflux from
the cell is mediated by the RFC, perhaps by the PCFT, and also by a series of
membrane transport proteins with ATP-binding cassette domains. ATP-binding cassette
transporters couple the energy of ATP hydrolysis to the translocation of various anion
and cation compounds, including folates and antifolates. Once inside the cell,
folylpolyglutamate synthetase (FPGS) adds glutamate residues to the monoglutamate
intrinsic to the folate structure. This increases its size and prevents its loss from the cell
via the folate export pumps.
In eukaryotes, cellular folates are located in two compartments, the
mitochondria and the cytoplasm. About 15-35% of folate resides in the mitochondria
and the remainder is in the cytoplasm. Folate is also present in the nucleus at very low
concentrations. In the cytoplasm, folate derivatives (5,10-CH2-H4PteGlu or 10-CHO3
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H4PteGlu) function as donors of one-carbon units in a series of metabolic pathway
involving de novo synthesis of purines and thymidylate, amino acid synthesis of
methionine, serine and glycine, as well as methyl group metabolism (Fig. 1). In the
mitochondria, folate is required for glycine metabolism and mitochondrial DNAencoded protein synthesis (Appling, 1991). Therefore, folates play a key role in DNA
synthesis and are essential for the survival of dividing cells and for growth. Folate
deficiency may impair the de novo biosynthesis of purines and thymidylate and thereby
disrupt DNA and RNA metabolism. Folate deficiency results in megaloblastic anemia,
which is characterized by many large immature and dysfunctional red blood cells
(megaloblasts) in the bone marrow, and also by multisegmented neutrophils. Folate
deficiency also impairs the homocysteine remethylation reaction, methionine synthase.
5-CH3-H4PteGlu is a co-substrate required by methionine synthase when it converts
homocysteine to methionine. Methionine is subsequently metabolized to S-adenosyl-Lmethionine (SAM), which is the principal methyl donor in the methylation of
macromolecules. Folate deficiency may lead to homocysteine accumulation, and the
resulting homocysteinemia is involved in cardiovascular disease and, embryonic defects,
particularly, neural tube defects (NTDs) and congenital heart defects. Folate deficiency
has been shown to contribute to genome-wide DNA hypomethylation and has been
claimed to result in activation of oncogenes and malignant transformation (Wu, 1994
Kim, 2004).
Folate plays an essential role in the synthesis of purines, thymidylate, and
remethylation of homocysteine to methionine (Anguera, 2006). Enzymes that require
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folates as a cofactor have been targets for chemotherapeutic agents, and several
therapeutic drugs have been developed that are aimed at these enzymes. For example,
dihydrofolate reductase (DHFR) plays a key role in the activation and regeneration of
folates. DHFR is the target for several early antifolate drugs such as methotrexate
(MTX) (Fig. 1). MTX is a folic acid analog that binds tightly to and inhibits DHFR,
prevents the formation of tetrahydrofolate, and ultimately disrupts DNA synthesis and
cell proliferation (Takimoto, 1996). 5,10-CH2-H4PteGlu is an important coenzyme for
the enzyme thymidylate synthase (TS), which transfers a one carbon unit from 5,10CH2- H4PteGlu to deoxyuridine monophosphate (dUMP) to generate thymidine
monophosphate (dTMP). Two antifolate drugs that are potent inhibitors of thymidylate
synthase have been developed, ralitrexid and pemetrexed. Inhibition of thymidylate
synthese by pemetrexed results in decreased thymidine triphosphate which is necessary
for DNA synthesis. Pemetrexed is now FDA-approved for first-line therapy for nonsmall cell lung cancer. It was originally discovered in this laboratory in collaboration
with Eli Lilly company and Professor Ted Taylor of Princeton University. It has been
shown that polyglutamylation of these antifolates greatly enhances their cytotoxicity
and that the enzyme folylpolyglutamate synthetase (FPGS) is responsible for the
conversion of the drug to the more active form (Synold, 1996).

Folate and antifolate polyglutamation
Folypoly-ɤ-glutamate synthase (FPGS) is essential for the survival of the
mammalian cell and is a major determinant of cytotoxicity and selectivity for antifolates.
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It is an ATP-dependent enzyme that catalyzes the addition of multiple glutamate
molecules to the naturally occurring folates, and the classical anti-folate cancer drugs,
such as methotrexate and pemetrexed. The highly anionic polyglutamate chain of
cellular folates (four glutamate residues or more) severely reduces export through the
cell membrane, which allows the retention and accumulation of folates and folate
analogues pools inside tumor cells (Moran, 1976.). Polyglutamyl derivatives of
endogenous reduced folates have a much higher affinity than the corresponding
unpolyglutamated forms for some, but not all, tetrahydrofolate cofactor-requiring
enzymes (Schirch, 1989.). For example, thymidylate synthase shows a 60% increase in
substrate affinity with the diglutamate derivative of 5,10-CH2-H4PteGlu compared to
the monoglutamate. This is also true for most antifolates; polyglutamated methotrexate
and pemetrexed have much higher affinity for thymidylate synthase and glycinamide
ribonucleotide formyltransferase than the parent drugs (Shih,et al. 1998).

The FPGS Protein
A crystal structure of mammalian FPGS has not been solved. However, the
structure of the MgATP complex of the enzyme from Lactobacillus casei has been
extensively studied.

The structural analysis of Lactobacillus casei FPGS (Fig. 2)

reveals that the enzyme consists of two domains, joined by a six-residue linker. The Nterminal domain (a.a. 1-294) consists of a large central β-sheet composed of seven
strands flanked by six α-helices and forms an ATP binding domain. The C-terminal
domain (a.a. 295-300) comprises a central six-stranded β-sheet flanked by four α-
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ATP
Enzyme active site
Conserve in all FPGS
sequence, important for
ATP binding

Ω-loop mediate
interaction with Cterminal via
hydrophobic
interaction

C-domain residues His316,Ser412,
Lys346 form a + platform for Lglutamate binding

Rossmann-like fold
Nucleotide binding domain
Similar with DHFR folate binding domain.

Figure 2. Ribbon diagram of L. casei FPGS
The N-domain is shown in blue, the C-domain in green and N-terminal in red. The binding domains were
indicated in the boxes. (This figure was modified from Sun, et al 2001. J. Mol. Biol.).
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helices with a Rossmann-like fold. This structure is composed of three or more parallel
beta strands linked by two alpha helices in the topological order beta-alpha-beta-alphabeta, which has structural similarly to dihydrofolate reductase, and contain a folate
binding site. The active site of the enzyme is located in a large inter-domain cleft
formed between the N- and C-domains, adjacent to two highly-conserved structural
motifs, an ATP-binding P-loop (a.a. 46-50 GTN(K)GK GS) and a Ω-loop (a.a. 72-81)
(Fig 2) (Sun, 1998, 2001). Binding of ATP and folate substrate triggers a large-scale
rigid-body rotation of the C-terminal domain. This conformational change brings
residues His 316, Ser412 and Lys346 of L.casei FPGS closer to the active site and
provides a positively charged platform for the binding of L-glutamate. Mutation of
these amino acid residues (H316A, S412A, Y414) have been shown to dramatically
decrease the enzyme affinity for L-glutamate and an almost complete loss of FPGS
activity. Substrate binding activate the FPGS and allow the enzyme to add a
polyglutamate tail to folate (Sun et al. 2001).
Amino acid substitutions in the C-domain could influence the three dimensional
structure of FPGS and disrupt folate and glutamic acid binding. The molecular docking
studies of L.casei FPGS by Tan et al., indicated that there are two possible sites for
binding folate substrates. One is for the folate tail and the other for the attacking
glutamate. Both binding pockets were capable of binding the longer folate and involve
the association of N-terminus domain residues R15-R85 and C-domain residue H316Y414. It appears that N-terminus residues R15, R82 and S73 are important in
complementing the growing glutamate chain (Tan et al, 2005).
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Mutagenesis

experiments suggest that the N-terminal domain plays a critical role at the enzyme
active site. Deletion of the first eight amino acids of human FPGS and modification of
Tyr3 had significant effect on FPGS activity (Qi et al, 1999).
The amino acid sequences of two species of FPGS expressed in the mouse differ
only by 18 amino acids at their N-terminus (Fig 2). The results of protein steady state
kinetic studies have shown that both isoforms have the same catalytic activity for the
production of polyglutamated folates (Andreassi and Moran, 2002). The isoform made
by P2 transcription was more sensitive to feedback inhibition by long chain
folypolyglutamates than the isoform made from P1. The enzyme produced in mouse
liver (the P1 isoform) was not affected by 5,10-CHO-H4PteGlu5, and H4PteGlu5 at the
concentrations that inhibited the activity of P2 isoform. The steady-state kinetics
analysis also showed some differences in substrate preference between the two mouse
isoforms. For example, the average turnover number (Kcat) for P1 isoform using 5CH3-H4PteGlu, 10-CHO-H4-PteGlu, and H4PteGlu as substrates was about double that
of the P2 isoform (Kcat =6.5/min). But the P1 isoform also has higher Km (7.6 uM) for
DDATHF, about 6 fold higher than the Km of the Ex1 isoform (Andreassi and Moran.
2002). The difference in substrate preference and feedback inhibition between the two
mouse isoforms may result from the differences of N-terminal amino acid sequence
which influence the three-dimensional structure of the folate binding site in the active
site. The decreased sensitivity of the FPGS P1 isoform to feedback inhibition by
folypolyglutamate cofactors may be an explanation of a larger folate cofactor
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accumulation in mouse liver and kidney than in rapidly proliferating tissues (Andreassi
and Moran. 2002)

The fpgs gene - Control of the two fpgs promoters
FPGS enzyme activity is found in both cytosolic and mitochondrial
compartments of mammalian cells; there are two consensus translational initiation
codons (AUG start codons) on fpgs mRNA species, and these are used for the
production of mitochondrial and cytosolic forms of FPGS (Fig 3). The translation
products differ by the presence of an amino-terminal mitochondrial leader peptide. The
first transcriptional initiation site generates a longer transcript encoding the
mitochondrial isoform of the enzyme; the second start site generates a shorter transcript
encoding only the cytosolic protein (Freemantle and Moran, 1995). The FPGS species
made from the upstream ATG was capable of trafficking to the mitochondria and is
responsible for the production of glycine (Turner et al, 1999).
The mouse fpgs gene is 21.5 kb long, contains 17 exons and 16 introns, and is
located on chromosome region 2qB (Fig. 3). Two species of cDNA have been isolated
from mouse liver and mouse leukemia cell L1210 cDNA libraries and by 5’-RACE;
they share identical sequences from exon 2-15, but utilize different initial exons (Roy,
1997; Turner et al, 1999). In dividing normal cells and all tumor cells, fpgs
transcription initiates from the downstream promoter (P2) and uses exon1. The
alternative transcript initiating at P1 and including exons A1a and A1b was used in
mouse liver and kidney. P1 is located about 10 kb upstream of P2, and both species of
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Exon A1a A1b

P2 transcript

ATG
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ATG
ATG

B

1

2 3

4

5

6 7 8

9

10 11

121314

15

Fig. 3. Comparison of N-terminal sequences of the fpgs P1 transcript in mouse liver and P2 transcript in leukemic (L1210). A,
sequence alignment of cDNA derived from P1 and P2. Both transcripts P1 and P1 contain identical exons sequences after exons 2.
The NH2-terminal domain of the cytosolic forms of the P1 FPGS and the P2 FPGS differ in sequence of 18 amino acids, as
indicated. B, a schematic of the alternative splicing patterns of P1 and P2 in the genome. Both transcripts contain two ATG start
codons the sequence between the 2 ATG is in frame and free of stop codons. The FPGS species made from upstream ATG for
either promoter was capable of trafficking to mitochondria. (This figure was modified from Turner et al 1999 Cancer Research).
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mRNA encode functional protein (61kd - 62 kd) (Andreassi and Moran,2002). The
human fpgs is located in chromosome region 9q34.1, and mRNA transcription initiates
from downstream promoter P2 and uses exon 1 in both dividing and differentiated
tissues. A recent study in this laboratory found that the tissue-specific expression of
mouse fpgs gene is controlled by at least three mechanisms. One was linked to DNA
methylation to control tissue-specific expression from the CpG-sparse upstream P1
promoter. The other is promoter occlusion preventing transcription from the
downstream P2 promoter when P1 is active (Racanelli et al, 2008). The third
mechanism is a poorly understood process involving tissue specific elongation of RNA
polymerase complexes assembled at P2. Binding of regulatory tissue specific proteins
to alternative promoters are often responsible for tissue-specific gene expression or
developmental stage-specific expression (Torik, 1996). However, the role of tissue
specific regulatory protein in control of transcriptional mutation from P1 or P2 is not yet
known.

Homologous recombination as a tool to study gene function
The mouse provides a powerful system to study mammalian genetics and to
produce animal models for human diseases. Gene targeting is the introduction of
defined sequence changes at a specific locus in the genome by homologous
recombination. This powerful technique has produced many advances in understanding
the function of specific gene products in mammalian development and is one of the
13

most valuable and definitive tools in current biology.

The major benefit of gene

knockout technology is that it enables the analysis of the function of a protein produced
from a specific gene in vivo in every cell type during development and into adulthood.
Gene targeting is achieved by transfecting embryonic stem (ES) cells isolated
from mouse blastocysts with specific gene-targeting vectors followed by introduction of
these recombinant ES cells into the mouse germline in vivo. Two type of targeting have
been used: conventional and conditional.

Conventional gene targeting vectors
Typically, this type of vector contains two regions of homology to the targeted
genomic locus placed on either side of a positive selection marker, such as the
neomycin (Neo), hygromycin or puromycin-resistance genes. Outside of the
homologous region, the herpes simplex virus thymidine kinase gene (HSV-tk) is most
often included in the construct to allow negative selection. When the targeting vector is
transfected into ES cells, a correct homologous recombination event will replace the
target gene sequences irreversibly with the replacement construct sequences. However,
genomic integration can occur not only by homologous recombination, but also by
random insertion. To produce ES cell clones that contain a correct homologous
recombination event, a combined positive and negative selection strategy is used.
Positive selection for resistance to neomycin, for instance, will eliminate most cells that
have not stably incorporated the construct into the genome. The negative selection for
14

exclusion of HSV-tk will enrich for homologous recombinant clones, since the
sequences of HSV-tk gene in the targeting vector, which are located outside of the
homology regions to the target gene, are lost during proper homologous recombination.
In contrast, during random integration, all sequences in the vector tend to be retained
because recombination usually occurs at the ends of the construct. In the presence of the
HSV-tk gene, the cells are sensitive to acyclovir and its analog gancyclovir. HSV-tk
allows the incorporation of gancyclovir into DNA, resulting in DNA chain termination
and cell death. Thus, cells that contain randomly integrated targeting vector which carry
the HSV-tk gene will be resistant to positive selection but will be gancyclovir sensitive,
whereas cells that contain homologous recombinants will be resistant to both positive
and negative drug selection (McCarrick, et al, 1993).

A correct homologous

recombination event has to be confirmed either by southern blot hybridization with a
DNA probe that is designed to be able to distinguish the correct homologous
recombination from the wild-type allele, usually by unique restriction enzyme digestion
pattern, or by PCR analysis with a gene-specific primer located outside the region of
homologous recombination and a targeting vector specific primer. The genomically
modified pluripotent ES cells will then be introduced into mouse germ line by injecting
the recombinant ES cells into recipient blastocysts (Waldman, 1988. Deng, 1992 ).
Disruption of a gene by conventional gene knockout in the mouse has advanced
our understanding of the function of numerous gene products in mammalian
development. The consequences of gene disruption in the germ line may have some
15

limitations. For example, the lack of a protein that serves one or more essential
functions during embryogenesis can result in early embryonic lethality and hence
blocks the experimental access to the study of its roles in later development or
adulthood. For some genes, the phenotype affects multiple lineages, making it difficult
to dissect individual functions. Furthermore, the effect of a germ-line mutation may also
be compensated for during development by redundant gene products, thus preventing
the appearance of an abnormal phenotype in the adult animal (Marth 1996. Rajewsky
1996. Lobe 1998. Metzger 2001).
Another limitation of conventional gene targeting also comes from the presence
of a selection marker gene in the targeted locus. PGK–Neo is a hybrid gene, consisting
of the phosphoglycerate kinase

I (PGK)

promoter driving the neomycin

phosphotransferase gene (Neo). It is a widely used selection marker for homologous
recombination in ES cells. Previous studies have suggested that targeted mutations that
retain the PGK–Neo cassette may yield unexpected phenotypes in ‘‘knockout’’ mice
due to the altered expression of neighboring genes within a locus (Olson, 1996). For
instance, a study by Christine et al. (1996) has shown that the insertion of PGK–Neo
into the granzyme B gene, the most 5′ gene in the granzyme B gene cluster, severely
reduced the normal expression of multiple genes within the locus, even at distances
greater than 100 kb from the mutation. The insertion of a PGK–Neo cassette into the βglobin locus control region also abrogates the expression of multiple globin genes
downstream from the cassette (Christine, 1996). Several other examples are known for
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which the positive selection gene disrupts normal function (Olson, 1996). For all these
reasons, the selection marker cassettes should optimally be removed from the targeted
locus after homologous recombination. This can be down by applying the Cre/loxP
system to generate conditional gene knockouts (Sauer, 1988) with the correct placement
of two loxP sites surrounding the drug resistance cassette (Fig. 6).

Cre/loxP conditional gene targeting vector
Conventional gene targeting leads to inactivation or modification of a gene in all
tissues of the body starting from the onset of development and continuing throughout
the whole life span. The conditional gene targeting approach, in contrast, is to
specifically delete a gene in a particular organ, cell type, or stage of development (Smith,
2000). The control of gene targeting in a time-dependent manner allows the
differentiation between effects of chronic versus acute depletion of a protein and also
the analysis of multiple protein functions at different time points in development. The
tissue-specific gene inactivation may define physiological roles of the gene product in a
certain tissue without compromising other functions in the organism (Muller, 1999).
Conditional knockout mice have other benefits over the conventional type. 1) They
often survive longer than conventional knockout mice. 2) Conditional knockout animal
allow more precise study of tissue or cell type specificity of the function of a gene
product. There are many conditional knockout models; however the most widely used is
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that based on the specific excision of a genetic element using the Cre-loxP recombinase
system.
Cre recombinase is a 35-kd enzyme isolated from bacteriophage P1 that acts as
a site-specific DNA recombinase (Kilby, 1993). The sequence recombined by Cre is a
34-bp sequence known as a LoxP site. A LoxP site consists of two 13 base pair (bp)
inverted repeats (a Cre recognition site) separated by an 8bp spacer (Fig. 4). The
asymmetrical 8bp spacer is responsible for the directionality of the loxP site. Binding of
Cre recombinase to two loxP sites that are in the same orientation will result in excision
of the intervening DNA, leaving one intact loxP site within the genome and the other on
the excised circularized fragment. If the loxP sites are arranged in the opposite
orientation relative to each other, Cre recombination will result in an inversion of the
intervening sequence (Fig. 4) (Martin J. 2000)
To generate a conditional gene knockout using the Cre/loxP system, two lines of
transgenic mice are required;
1)

A mouse strain that carries the target gene or gene fragment flanked by two loxP

sites in the same orientation and positioned in a way that it does not prevent normal
gene activity. Thus, the conditional targeting vector is designed in the manner that loxP
sites are inserted outside of coding regions, usually in an intron in a position that does
not interfere with regulatory regions or exon splicing. The Cre recombination of these
loxP sites will result in excision of a DNA fragment that inactivates the gene or results
in an inactivate gene product. The neomycin or similar drug resistance gene is also
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Directional recombination by CRE of LoxP sites
A.
CRE recognition

Spacer

Cre recognition

5’ - ATAACTTCGTATA GCATACAT TATACGAAGTTAT- 3’
3’ - TATTGAAGCATAT CGTATGTA ATATGCTTCAATA- 5’

B.

Cre mediated deletion

C.

Cre mediated inversion

Neo

Neo
Cre recombinase

Neo
Neo

Fig 4. Recombination of loxP by Cre recombinase (A). 34bp sequences recognized by Cre recombinase. Two 13bp
inverted Cre recognition sequences separated by an 8-bp spacer construct a loxP site. (B) and (C) Directional of
loxP sites and Cre recombination,
indicates loxP site and orientation. Where sites are in the opposite orientation
the DNA is inverted during the recombination event.
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included in the vector for the selection of correctly targeted ES clones. However, the
drug resistance gene included for the selection usually includes more than a kilobase
(kb) of foreign DNA, which has the potential to influence the expression of the targeted
gene prior to excision. To minimize this influence and remove the resistance gene, an
additional loxP site is often inserted to flank the resistance gene. This will allow
excision of the resistance gene from correctly targeted ES cell clones in vitro by
transient expression of Cre recombinase prior to blastocysts microinjection. The final
targeting vector would thus include three loxP sites: two positioned flanking the
resistance gene, the third located to cause the desired deletion of the target gene when
timed recombination occurs. For efficient and site-specific integration of the targeting
vector into the ES cell genome, the targeting vector also contains two homologous
regions identical to DNA sequences that flank the targeting region up- and down-stream
of the negative selection marker. HSV-TK gene is also included in the construct at either
end of the homologous recombination region to decrease the frequency of survival of
random recombinants and, hence, enrich for homologous recombination ES cell clones.
2)

To achieve spatially or temporally controlled somatic mutations, the second Cre

transgenic mouse line is required that expresses Cre recombinase under the control of
either a tissue-specific or a time-specific inducible promoter. This mouse is generated
by standard oocyte injection techniques, or by knock-in gene targeting behind a suitable
promoter. Up to now, many different transgenic mouse lines expressing tissue-specific
Cre recombinase have been generated and are commercial available from the Jackson
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Laboratory (Bar Harbor, ME). For instance, Postic and Magnuson (2000) have
generated an albumin-Cre transgenic mice line in which the promoter and upstream
enhancer of the rat albumin gene were used to direct the liver-specific expression of Cre.
This modified version of Cre contains a rat albumin enhancer/promoter fragment, a
nuclear localization signal sequence, and a translation start site optimized for eukaryotic
cells (Postic, 2000). Metzger and Chambon have generated a mouse line expressing the
tamoxifen-activatable Cre recombinase (Cre-ER) specifically in the proximal tubule
cells of the kidney. In this system the Cre recombinase is encoded as part of a hybrid
gene consisting of the Cre gene fused to a mutant form of the ligand binding domain of
the estrogen receptor (ER), which is insensitive to the natural ligand (17β-estradiol) but,
following binding of the synthetic estrogen antagonist tamoxifen, permits Cre–ER
translocation from the cytoplasm to the nucleus, and allows the temporally-controlled
inactivation of floxed target genes by excision (Metzger, 2001). Also, the tetracyclinedependent system developed by Gossen and Bujard activates transcription of the
recombinase in a spatio-temporal manner. In this system, Cre expression is under the
control of the tet system in which a transactivator tTA binds in the absence of
tetracycline (tet) to an engineered tet-operator and activates the transcription of the Cre
gene (Gossen, 1992). Mating of these mouse lines with a target mouse carrying a
modified allele flanked with two loxP sites will generate a generation of animals with a
tissue-specific gene deletion.
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Genetic background of homologous recombinant mice
Genetically modified mice provide a powerful system for understanding the
function of specific gene products in mammalian development and as models of human
genetic diseases. However, transgenic and knockout mice are generated in a variety of
inbred strain backgrounds. These background strains have been selected for ease and
convenience of generating the transgenic or knockout mouse lines. For example, many
targeted mouse strain have been generated by using ES cells derived from 129 substrain of mice, because the ES cells derived from this strain have the ability to
contribute to the mouse germ line even after extensive manipulation in culture.
C57BL/6-derived blastocysts are the most common hosts of ES cells lines for
generation of germ-line transmitting chimeras, especially with the 129-derived ES cells.
It is most often the case that 129-derived chimeras are bred with C57BL/6 females to
allow monitoring germ-line transmission by coat-color markers and also to speed up
breeding, since 129 strains are poor breeders (Festing, 1996). This will generate a
mouse with a mixed 129 x C57BL/6 genetic background. However, 129 mice are not
derived from a single strain of mice; they are actually a diverse and complex family of
sub-strains. The genetic background of 129 strains could interfere with phenotypic
analysis of a targeted mouse.

For example: 129 and C57BL/6 are very different

genetically and behaviorally. Genetically differences were demonstrated by their
polymorphic genetic markers. Behaviorally differences involve learning, memory,
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anxiety, and pain response. C57BL/6 mice are not anxious, are more active and good
learners, and perform well in a water maze. In contrast, 129 mice are more anxious, less
active, poor learners and perform poorly in a water maze. Another example of
background dependent phenotype variation is the postnatal phenotype of TGF-β1
knockout mice. On the mixed background of 129/sv X C57BL/6 approximately 50% of
TGF-β1 KO mice survive to birth and develop an autoimmune-like inflammatory
disorder that affects most organs (Marion. 1995). In constrast, only 1% of TGFβ1
knockout embryos in C57BL/6 genetic background live to birth and develop
inflammatory disorder, the rest die before birth. This indicated that the phenotype of the
embryonic lethality of TGFβ1 knockout is quite strain dependent. Donehower et al.
monitored a large number of p53-deficient mice in two different genetic backgrounds
129/sv and C57BL/6 X 129/sv. They found that both p53+/- and p53-/- with 129/Sv
genetic background mice had an accelerated tumorigenesis rate compared with their
p53-deficient counterparts of mixed C57BL/6 × 129/Sv genetic background
(Donehower. 1995).

These studies also clearly demonstrated that the genetic

differences between inbred strains can profoundly influence the knockout mouse
phenotype. To reduce this influence, successfully targeted mice initially in the 129/sv
background can be bred to a desired background strain for eight generations to obtain
more than 95% pure genetic background. C57BL/6 is the most widely used mouse
strain in a variety of research areas including cardiovascular biology, developmental
biology, diabetes and obesity, genetics, immunology, and neurobiology research.
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Many gene-targeted mouse strains are commonly backcrossed to C57BL/6 for
more than ten generations to generated a congenic mouse strain. However, crossing two
inbred stains (for example, 129sv X C57BL/6) results in a mixed genetic background.
The F1 generation will be isogenic, because they share all wildtype genes and are
heterozygous for the alleles inherited from the parental strains (one allele from 129 sv
and the other from C57BL/6). Further intercrossing of F1, results in the generation of
F2 and F3, where the alleles will segregate according to the chromosomal locations and
cross-over frequencies during gametogenesis. Gene alleles on the same chromosome
can be separated and go to different daughter cells. The further apart the alleles are on
the chromosome, the greater the probability of allelic segregation. In general, the
contribution of genetic material from parental strains to daughter strain is usually 50/50.
Subsequent C57BL/6 backcrossing reduces the number of 129 genes that flank the
mutated locus. However, even after 12 generations of backcrosses, at least 6.6
centimorgans (cM*) of the genetic material surrounding the targeted locus will be
derived from the ES cell strain, usually 129/sv, rather than from the breeding strain
(C57BL/6). The 6.6 cM of DNA corresponds to 13 million base pairs (Mbp) of DNA
sequence and could have as many as 110 genes in it (Schalkwyk, 2007). Therefore, it
would be dificult to determine whether phenotypic differences observed between
homozygous deletion mice and wild-type control littermates are the result of the gene
deletion or due to the effect of other genes closely linked to the mutated gene locus.
Recently, the “speed congenics” method have been developed to aid in the generation of
24

congenic strains (Wong, 2002). This method uses polymorphic genetic markers to
screen the progeny of each backcross generation for the “best male” for subsequent
mating. Speed congenic breeding greatly accelerates the production of congenic mouse
with maximal recipient genome contribution.

Statement of the problem addressed in this thesis
As explained in more detail above, there are two isoforms of the FPGS protein
expressed in mouse tissues (Fig. 2). In mouse liver and kidney, the fpgs transcript is
initiated from an upstream promoter (P1) and includes A1a and A1b exons in the
mature mRNA. In all dividing tissues, the fpgs transcript is initiated from the
downstream promoter (P2) and includes exon1 in the mature mRNA. To better
understand the potential pathophysiological and pharmacological importance of the
FPGS isoforms expressed in mouse liver and kidney, we decided to generate a knockout
mouse specifically lacking P1 and exons A1a and A1b, but to still contain an otherwise
normal fpgs locus. It was not known whether the deletion of the upstream promoter and
exons (A1a and A1b) of fpgs would lead to early embryonic lethality. To overcome the
possibility of an early lethality problem, a Cre/loxP conditional gene-knockout strategy
was chosen for our targeting vector construction.
In this study we try to understand why the mouse has evolved to use the
upstream P1 promoter instead of downstream P2 in liver and kidney, whether the two
promoter system used in the mouse is essential for development, whether the deletion of
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the upstream promoter and exons activate the down stream promoter, and whether the
promoter interference observed in mouse FPGS collapses to the simpler system used in
humans upon genetic deletion of the promoter used in mouse liver and kidney.

* cM, is a unit of recombination frequency for measuring genetic linkage. It is often
used to indecate the distance along a chromosome. 1cM = 1% chance that a marker at
one genetic locus on a chromosome will be separated from marker at a second locus due
to crossing over in a single generation.
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CHAPTER 2: Materials and Methods
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LoxP cassette generation
The LoxP cassette (Fig 7) was generated by annealing two equal amounts of
complementary oligonucleotides (5ug) in a total volume of 90 ul in a 1.5 ml
mirocentrifuge tube. The tube was placed in a glass beaker containing 300 ml of boiling
water for 5 min; the sample was then allow to cool to 700C, and 10 ul of 10X SuRE/Cut
buffer B (100 mM Tris HCl (pH8), 100 mM NaCl, 50 mM MgCl2, and 10 mM 2mercaptoethanol) were added and the reation mix was allowed to continue to cool to
room temperature in the beaker containing 300 ml H2O. The sample was
phenol/chloroform extracted, EtOH precipitated, resuspended in H2O and used for
ligation. This LoxP cassette was designed with SalI and XhoI ends for convenient
insertion of the loxP site upstream of the P1 promoter in the targeting vector.

Gene targeting on ES cell
The PKO2lx FPGS-A1aA1b construct (Fig. 6) was linearized by digesting with
Bot I and an aliquot was run on an 0.8% agarose gel to confirm complete linearization.
The linearized targeting vector was then phenol-chloroform extracted, ethanol
precipitated and re-suspended in sterile TE (10 mM Tris, pH 7.5, 0.1 mM EDTA) at a
concentration of 1 ug/ul. A total of 30 ug DNA was electroporated (250 v volts, 500 uF
capacity) into 5 X 107 129/Sv ES cells by Mrs. Herju Zhang at the Transgenic core
Facility. Forty-eight hours after electroporation, 150 ug/ml of the positive selection drug
G418 and 2 mM of negative selection drug ganciclovir (GANC) was added. The culture
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medium was changed every 2 days and selection continued for 12-14 days. Surviving
clones (192) were picked into individual wells of two 96 well plates that contained
primary mouse embryo fibroblasts (MEFs) feeder cells and expanded into three plates.
One plate was cryopreserved in 10% DMSO and stored at -80 oC to provide early
passage stocks of the clones. Genomic DNAs were extracted from the remaining two
plates for genotyping to identify ES clones in which homologous recombination had
occurred.

Genomic D A isolation from ES cells in 96 well plates
Once the selected clones reach confluence, the plates were washed twice with 1x
PBS ( 100 ul/well/96well plate) and lysed in 50 ul/well of Lysis Buffer (10mM Tris
pH 7.5, 10mM EDTA pH 8.0, 10mM NaCl, 0.5% Sarcosyl, and 1 mg/ml Proteinase K )
overnight at 60oC in a humidified chamber. The next day, the genomic DNA was
precipitated with 100 ul of cold absolute ethanol that contained 75mM NaCl. The plates
were incubated at the room temperature for 15 min – 30 min or until the precipitated
DNA was clearly visible. DNA was washed with 70% ETOH in the well and allow to
air dry. Genomic DNA from each clone was re-suspended in 50 ul ddH2O, and 3 ul of
genomic DNA from each clone was used for PCR analysis.
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Identification of homologous recombinant ES clones
To identify the ES clones that contained the fpgs homologous recombinant allele,
a long range PCR assay was designed using two sets of primers. 1) Primer 4309 and –
Neo1B: Primer FPGS+4309 (CAG AAG TTT CTG CCA CCT CCC AAT) sequences
were located at the 5’ intron outside of the homologous recombination region contained
in the targeting vector. The anti-sense primer Neo 1B (CAT TCG ACC ACC AAG
CGA AAC ATC) contained Beo gene specific sequence. Together, these primers would
amplify a 6.4kb DNA fragment if the genomic DNA of a cell contained the properly
inserted homologous recombinant fpgs sequence. 2.) Primer-15459 and +ECB (Fig. 9a).
The primer “+ECB” (GAT CGA TCC TAG AGA ATT CCT AGA CCG) was targeting
vector-specific sequence, located over the unique restriction sites (EcoRI ClaI BamHI)
downstream of the loxP3. The anti-sense primer -15459 (ATT GCA TAT CTG TGG
AGG TCA GGG) was located in the third intron of fpgs gene sequence, outside of the
sequence used as a 3’ homologous region in the targeting vector. This set of primers
would amplify a 5.2 kb DNA fragment from the targeted fpgs genomic locus.
The genomic DNA of ES cells were assessed by PCR using 20 ul Platinum
HIFI Taq DNA polymerase High Fidelity Master Mix (Invitrogen) combined with 0.31
U Pfu Turbo DNA polymerase (Stratagene) and 2ul of PCR primers (75 ng of each
primer was added in each reaction). A touch-down PCR program was used: initial
denaturation at 94 oC for 4 min, followed by 5 cycles of denaturation at 94 oC for 30
second, annealing at a melting temperature of 60 oC for 30 sec, extension at 72 oC for 12
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min, then followed by 30 cycles of denaturation at 94 oC for 30 sec., annealing at a 58oC
for 30 sec, extension at 72oC for 6 min. followed by one final extension at 72oC for
15min. PCR results were analyzed by electrophoresis on 1% agarose gels in 1X TAE
buffer at 30 v overnight ( at room temperature).

Southern blot analysis
The positive clones identified by PCR analysis, were recovered from a well of
cryopreserved cells on a 96 well plates and expanded into three 100 mm tissue culture
dishes with MEF feeder cell. After the cells reached confluence, genomic DNA was
extracted from these ES cells for DNA analysis in accordance with the manufacturer’s
(Gentra) protocol. After purification, 20 ug of genomic DNA were digested with SacII
(Fig. 11), fractionated by electrophoresis in 1% agarose gels with “1kb plus” size
markers (Invitrogen), and transferred to a Hybond-N nylon membrane (Amersham).
After blotting, membranes were UV cross-linked by using a Stratalinker (Stratagene).
The 275 bp DNA probe was obtained by PCR from plasmid pGEM1Z-A1a with FPGS
9047 and FPGS 9322 (Table 1), primers which are located on fpgs gene upstream exon
A1aA1b. DNA probe was randomly primed and labeled with [α-32P]-dCTP using a
random primer DNA labeling system from Invitrogen. Hybridization was performed
overnight at 65oC in Denhardts hybridization solution. Membranes were washed at 50oC
(15 min each) in the solution that contained 0.1%SDS and 2xSSC. The washed
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membrane was exposed to film (X-OMAT AR, Kodak) for 2 days at -80 oC using
double intensifying screens (Fig8).

Cre Excision in Targeted ES cells
To eliminate the interference of PGK-Beo, the pCMV-cre plasmid (10ug) was
introduced into the correct targeted ES clone 2D-6 (5x106) by electroporation. After two
days cultured, the cell were seeded at 500-2000 cells per 100 mm dish to form colonies.
About twenty-four clones were picked after two weeks of culture and each clone was
seeded in duplicated plates. One set was grown in selection media with 180 ug /ml
G418. The duplicate plate was used to expand the G418-sensitive (This was done by
Mrs. Herju Zhang in the Transgenic Mouse Facility at VCU).

Mice
a. Mice housing
All experimental mice were born and raised in the animal facilities at the
Virginia Commonwealth University. The A1aA1b knockout mice used in this study
were C57BL/6 and 129Sv mixed genetic background or backcrossed for more than six
generations in C57BL/6. C57BL/6 mice were obtained from Charles River Laboratories.
Unless used for the folate deficiency dietary study, all mice were maintained on
standard rodent chow mix. Mice were kept under a 12:12-h light-dark cycle in a
temperature-controlled facility (25oC) with free access to food and water. The mouse
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reaches sexual maturity by six weeks of age; all the mice matings were set up after six
weeks of age, and at the ratio of 1-2 female / male. Gestation normally lasts 19-21 days.
The progeny of these matings were genotyped at weaning age (3-4 weeks of age) and
the genotypes were determined by PCR of tail DNA (as described below). After
weaning age, 4-6 mice were housed per cage.

Heterozygous F1 females were

intercrossed with heterozygous F1 males to generated F2 homozygous KO mice.

Growth curve analysis
Twenty four weaning age mice (4 weeks of age) obtained from each genotype
group with C57BL/6 background (F6), (homozygous (-/-), heterozygous A1aA1b
knockout (+/-) and wild type (+/+)), were used for a growth rate study. Each group
contained twelve males and twelve females mice, the male or female mice were then
divided into two sub-groups; one sub-group (six male or female mice) received normal
amino acid-based diet, which contained 1300 ug folate per kg diet and 1%
succinylsufathiozole (Purina, Test Diet, 5S4Q, irradiated ½” pellets). The other subgroup (six male or female mice) received a low folate diet, which contained 63 ug folate
per kg diet and 1% succinylsufathiozole (Purina, Test Diet; 5T2L, irradiated ½” pellet).
The body weight of mice were measured twice a week, start at weaning age. The mouse
weights were recorded for ten weeks after initiation of feeding with each test diet.

33

Genotyping of offspring
Tail genomic DNA was prepared using an in-house protocol: Three week old
weaning mice were marked by ear punching and a 0.5 cm tail tip was cut and digested
in 500 ul of Tail blot solution (50mm Tris-HCl pH 8, 100 mM EDTA, 100 mM NaCl
and 1% SDS) at 55oC overnight. The mixture was extracted with phenol/chloroform
(500 ul) once and the DNA was precipitated in 99-100% isopropanol and spool with a
capillary pipette, washed in 75% EtOH and 100% EtOH, air dried for 5 minutes, and
then re-hydrolyzed in 200 ul TE buffer (10 mM Tris-Cl, pH 7.5 1 mM EDTA).
Genotyping were performed by PCR analyses. Primers FPGS+9047 5’-TGC
GAA CCT CTC AGG TAA ACA CTC-3’ and FPGS-9322 5’-CCT GAA AGG AGG
CAG TCT TAG CTT-3’ were used to amplified a 275 bp DNA band from the wild type
allele, Primer FP1 5’-TGA GTC AGT AGG CTC AGT GTG AGA-3’ and -ECB 5’GAT CGA TCC TAG AGA ATT CCT AGA CCG-3’ were used to amplified a 175 bp
DNA band from any knockout allele (Fig 15 ). The conditioned knockout allele was
analyzed by fpgs intronic primer FPGS-9860 5’-TCG CTT GTC TAC CAC GCA CTG
TAA-3’; and FPGS-10355

5’-TGT TCA GGC ATG TCA CAG AGT CCA-3’; This

PCR will produce a 495bp fragment from the wild-type gene and a 576 bp fragment
from the conditional knockout allele (Fig 10). PCR amplification was carried out in 20
ul Platinum HIFI Taq DNA polymerase High Fidelity Master Mix (Invitrogen)
containing 75 ng of each primer and 80 ng of genomic DNA as template. After a 3
minute denaturation at 94oC, the PCR was performed on the following program for 35
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cycle: 35 sec 94oC; 35 sec 58 oC; 45 sec 72 oC, with a final extension step of 5 minute
at 72 oC. The PCR products were analyzed on 1.2% agarose gels containing ethidium
bromide (Fig 15).

RT-qPCR
Total RNA was isolated from liver, kidney, spleen, bone mallow and intestine of
congenic litter mates using the TRIZOL Reagent (Invitrogen) according to the
manufacturer's instructions; Mouse liver was first perfused through the portal vein with
5-10 ml cold 1x PBS, and about 150-200 mg of liver tissue was isolated and
homogenized in 3ml TRIZOL Reagent with a Douncer homogenizer. SuperScript III
First-Strand Synthesis System (Invitrogen) was used for first-strand cDNA synthesis;
5ug total RNA and oligo-dT was used in this reaction. About 25ug of cDNA was
synthesized and ~ 1 ug or 1 ul cDNA were used for real time PCR.
Primers for mouse fpgs and β-actin, were designed using IDT (Integrated DNA
Technologies) SciTools’ Primer Quest and these primers were synthesized by IDT
(Table 1a). All primers were then tested to ensure amplification of single bands with no
primer-dimers. Primer sequences were as follow: for fpgs gene expression analysis: For
β-actin gene expression; forward primer + actin sn 5’-GAC CCA GAT CAT GTT TGA
GAC C-3’, reverse primer: - actin asn, 5' - ATC AGA ATG CCT GTG GTA CGA C 3'. Together these primers would produce a 150 bp PCR product. Primer A1aA1b-A
was located in the sequences of exon A1a (5’-TGT GCA CAG GAT GGA AAT GCG
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AAC C-3’), and its anti-sense primer –Ex3a (5’- TGT TTA GCC GGT TCA AGT CCT
CCA – 3’) was located in the fpgs cDNA sequences of exon 3. Together, these primers
would amplify a 340bp cDNA fragment from P1 fpgs mRNA species. Primer Ex1 (5’CTA GCT TGC GGT GGC ATT AAG ACT- 3’) was located in the sequences of exon
1(Fig. 21), which was used in the transcript made from P2. Primer Ex1 and anti-sense
primer -Ex3a can amplify a 343 bp cDNA fragment from P2 fpgs mRNA species. The
real time PCR results were normalized to the mouse actin gene to control for the cDNA
loading in the reaction.. The FPGS gene expression levels were quantified either using
absolute external plasmid standards quantification or calculated as 2∆Ct method using a
reference gene (Bio-Rad Real-time PCR applications Guide).
PCR products using the primer pairs fpgs-A1aA1b-Ex3a, fpgs-Ex1-Ex3a, and
mouse β-actin sn and asn were ligated into the TOPO-TA cloning vector (Invitrogen),
and transformed into TOP10 competent cells (Invitrogen). Mini preps of isolated
plasmid DNA were then prepared (Promega). Before use, the plasmid concentration
was determined by measuring the absorbance at 260 nM (A260) in a spectrophotometer
(NanoDrop). To generated standard curves, the plasmids were serially (1:100) diluted in
HPLC grade water (Fisher) over the appropriate concentration range (usually from
1ng/ul, 10-2ng/ul, 10-4ng/ul, 10-6ng/ul, and 10-8ng/ul).
Bio-Rad Mini Opticon Real-Time PCR System was used for DNA amplification
and data collection. Reactions were carried out in triplicate in a 25ul volume containing
2 ul reverse-transcribed cDNAs, 12.5ul 2xSYBR Green Master Mix, and 75ng of each
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forward and reverse primer. The reactions were cycled with a pre-incubation step of 15
minutes at 95oC followed by 40 cycles of 30 seconds at 94 oC, 30 seconds at 58 oC, and
30 seconds at 72 oC. Fluorescence data was collected at the end of the extension. The
raw data were analyzed and normalized with respect to β-Actin expression. Ct values
were exported into a Microsoft Excel worksheet for calculation of gene expression in
accordance with the power (2- delta Ct) method (Bio-Rad, Real-time PCR applications
Guide). The levels of gene expression in knockout mice were represented with respect
to those in wild-type animals as knockout/wild-type ratios.

Average 2∆Ct target (target-Actin)
Ratio =

X 100

Average 2 ∆Ct ref (control-Actin)
Table 1a – Primers for qPCR analysis of fpgs gene and housekeeping ( GAPDH and β-Actin) gene
Target gene

primer name

Fpgs -A1aA1b isoform:

A1aA1b-a
-Ex3a

Fpgs – Ex1 isoform:

+Ex1
-Ex3

Fpgs

Primer sequence
Sense
Anti-sense

Product size

5’-TGT GCA CAG GAT GGA AAT GCG AAC C-3’
5’-TGT TTA GCC GGT TCA AGT CCT CCA-3’

300 bp

Sense
Anti-sense

5’-CTA GCT TGC GGT GGC ATT AAG ACT-3’
5’-TGT TTA GCC GGT TCA AGT CCT CCA-3’

300 bp

Ex3F
Ex6R

Sense
Anti-sense

5’-TCATGTCACTGGGACCAAAGGGAA-3’
5’-AGACATGGCTGTCGTCCTTGAACT-3’

218 bp

GAPDH

F177
R177

Sense
Anti-sense

5’-ATG ACA TCA AGA AGG TGG TG-3’
5’-CAT ACC AGG AAA TGA GCT TG-3’

177 bp

β-actin

sn
asn,

Sense
Anti-sense

5’-GAC CCA GAT CAT GTT TGA GAC C-3’,
5'-ATC AGA ATG CCT GTG GTA CGA C - 3',

155 bp
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FPGS microassay.
Animals were anesthetized with Isoflurane (Baxter) and sacrificed by cervical
dislocation. Whole mouse liver were quickly perfused with PBS, then removed and
whole liver was homogenized in 1mL lysis buffer [100mM Tris, pH 7.9 (at 25 °C), 2
mM dithiothreitol (DTT), 2 mM ATP, 5 mM MgCl2, 0.05% n-octylglucoside,
0.01mg/ml leupeptin, 0.01mg/ml Aprotinin, 5mM EDTA and 2 mM EGTA]; Tissues
were disrupted using a dounce homogenizer for 20 strokes. Homogenate was
centrifuged at 160000g (36000 rpm at Beckman optima-L-80 XP autra-centrifuge in
SW 55 Ti Rotor) for 1 hr at 2oC. The high-speed supernatant fraction 110 ul was passed
through a Sephadex G-50 spin column (1 ml) to remove any glutamic acid present in
the sample that would interfere with the assay and 2.5 ul of supernatant were used
directly for FPGS assay. The first reaction was carried out in a total volume of 10 ul for
crude cytosols: FPGS substrate solution 5 ul ( 800 mM Tris-HCl, pH 8.5 (25oC) 40 mM
MgCl2, 120 mM KCl, 20 mM ATP 4 mM L-[3H]glutamic acid, the specific activity:
1000cpm/pmole of glutamic acid, 20 x 10-6M (6-S)-tetrahydrofolate and 0.5% 2mercaptoethanol ), 2.5 ul of crude sample and 2.5 ul buffer A ( 50 mM Tris-HCl pH 8.5,
10 mM MgCl2, 2 mM DTT, 1 mM phenylmenthylsulfonyl fluoride) were mixed in 0.6
ml Eppendorf tubes on ice, the reaction was started by transferring the tubes to a 37oC
water bath, and the stander reaction was last for 15 min and ended by transfer to ice for
2 min., Any FPGS present in a sample mixture catalyzes the addition of [3H]-glutamate
to tetrahydrofolate to form -tetrahydropteroyl-diglutamate. The second reaction was
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started by addition of 100 ul of fresh made thymidylate synthase solution (30 mM
Na2HPO4 pH 7.2, 8 mM 2-mercaptoethanol, 10 mM formaldehyde, 2 uM FdUMP, 0.1
mg/ml bovine serum albumin, 0.3 uM thymidylate synthase) and 30 min incubation in
37oC. The reaction was ended by transfer the tube to ice. During the second reaction,
tetrahydrofolate was nonenzymatically converted to 5,10-methylenetetrahydrofolate and
a covalent complex was formed among 5-10-methylenetetrahydrofolate, FdUMP , and
thymidylate synthase. To ensure all the [3H]-tetrahydropteroyldiglutamate in the
reaction wereight complex containg the e bound in a covalently bound macromolecular
complex, the excess FdUMP and thymidylate synthase were added. The high molecular
[3H]-tetrahydropteroyl-diglutamate was separated from free L-[3H]glutamic acid by
passing the reaction mixture through a Sephadex G-50 spun-column ( 1.1 ml ). The
columns were centrifuged at 400 rpm for 5 min and followed by 2 min. at 2400 rpm in
Beckman J-6 centrifuge and the radioactive samples were collected in the miniscintillation vials. 5 ml Scintillation liquid was added to each vial, and the tritium in the
samples was determined by liquid scintillation counting. Enzyme activity was
calculated by count per/min./ microgram of total protein (Antonsson and Moran , 1990).
Protein concentrations were determined by the Bradford dye-binding procedure
( Bradford,: 1976)
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FPGS, ATP, Mg2+
H4PteGlu + [3H]Glu

H4PteGlu([3H]Glu)n

H4PteGlu([3H]Glu)n + H2CO + TS + FdUMP

TS.FdUMP.5.10-CH2- H4PteGlu([3H]Glu)n
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CHAPTER 3: Results
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In mouse tissues, two isoforms of the FPGS protein are expressed. One isoform
is expressed in all rapidly dividing cells, and transcription that produces this isoform is
initiated from P2 and the mature transcript includes exon1. The other isoform is only
expressed in a few differentiated tissues (liver and kidney); this transcript uses the
upstream promoter (P1) and the initial sequence is from exons A1a and A1b. In the
adult human, almost all fpgs transcripts in both dividing and differentiated tissues are
initiated from Exon1 and use only the P1 promoter. The role of the fpgs transcript
expressed in mouse liver has not yet been studied during development. Is the two
promoter system used in the mouse essential for development? Will the deletion of the
upstream promoter activate or up-regulate the FPGS P2 transcription in mouse liver and
kidney? Will the promoter interference used in mouse fpgs collapse to the simpler
system used in humans upon genetic deletion of the promoter used in mouse liver and
kidney? What are the differences in folate metabolism in these mutant mice? To better
understand the evolution of two mouse FPGS species, we decided to knock out the P1
promoter and Exons A1a and A1b in the mouse genome.

Gene targeting vector construction
There are two types of gene targeting: conventional and conditional.
Conventional gene targeting leads to the deletion or mutation of a gene in all tissues of
the mouse from embryonic development throughout adulthood.

Conditional gene

targeting is aimed at controlling gene targeting in a time- and tissue-dependent manner.
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When the global removal of the gene of interest results in embryonic lethality, the
conditional knockout will be the method of choice for studying the gene function during
later stages of development (Muller, 1999). It was not known whether the deletion of
the upstream promoter and exons A1a and A1b of fpgs would lead to early embryonic
lethality. What is the function of the P1-derived FPGS isoform in late development and
in the adult? To overcome the possible early lethality problem, a loxP/Cre conditional
gene-knockout strategy was chosen for our targeting vector construction.

Selection of homologous recombination regions for targeting vector construction
Two contiguous HindIII genomic DNA fragments of fpgs from mouse 129/sv
BAC library were previously cloned into a modified p GEM4 (Promega) vector
(pGEM-LZ) by a former graduate student in this laboratory, Fiona Turner (Turner et al.
1999). The plasmid pGEM-LZ-A1a contained an 8.5 kb HindIII genomic fragment,
which includes the sequences of the P1 promoter and exons A1a and A1b (Fig. 5). The
other plasmid, pGEMLZ-Ex1, contains a 7.1 kb HindIII genomic fragment, which
included the P2 promoter and Exon 1. The sequences of these two clones were analyzed
by extensive restriction mapping during Dr. Turner’s dissertation, and more recently
was compared to the NCBI mouse genome resource sequence of the fpgs gene. The
location of the experimentally determined restriction endonuclease sites relative to the
positions of intron and exon sequences on the clones were identical to the NCBI mouse
fpgs sequence (Fig. 5).

The results show that two HindIII sites were located
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Fig 5. The Mapping of restriction enzyme sites on mouse fpgs gDNA sequences surrounding exons A1a and A1b and
exon 1. A Hind III-XhoI fragment was selected as the 5’ homologous recombination region, and the ajacent XhoI –
SpeI fragment was selected as the 3’ homologous recombination region.
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sequentially in the mouse genome; these two clones (pGEM1Z-A1a and pGEM1Z-Ex1)
were used as the backbone of the targeting construct.
The total length of the homologous DNA regions on the targeting vector is one
of the most important parameters that affect the targeting frequency at a particular
genetic locus. It has been shown that increasing the length of total homology
dramatically increased the absolute targeting frequence (Deng,C and Capecchi, M.R.
1992).

Therefore, 3.2 kb of HindIII -Xho1 region present in the 5’ fpgs gene intron

upstream of the P1 was selected as a 5’ homologous recombination region. The 4.85 kb
of Xho1-Spe1 region, present in the intron 3’ to exon A1b, was selected as a 3’
homologous recombination region (Fig. 5).

Construction of the targeting vector
The targeting vector pKO Scrambler NTKV (Stratagene) (Fig. 6) contains a
drug resistance gene and the neomycin phosphotransferase gene (Beo) driven by the
phosphoglycerate kinase gene (PGK) promoter. This marker would allow the positive
selection of cells that contain the targeting construct integrated in the cellular DNA. On
both sides of a Beo selection marker reside two multiple enzyme cloning sites (MCS)
for the cloning of the homologous recombination regions. This targeting vector also
contains the herpes simplex virus thymidine kinase gene (HSV-tk) - a negative selection
marker; retention of the HSV-tk gene in a mammalian cell renders that cell sensitive to
the guanosine analog, gangcyclovir (GANC). Some studies have shown that retention of
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Fig. 6 The construction of the pKO2lxFPGS-A1aA1b conditional knockout targeting vector. (a) Schematic diagram
showing the DNA enzyme restriction sites and relative location of loxP sites and homologous recombination regions
after planned insertion into the mouse genome. The targeting vector was designed by placing a PGK-Beo selectable
marker, flanked by loxP sites ~1kb downstream of coding exons A1a and A1b. The upstream promoter and coding
exons A1a and A1b of fpgs were also flanked with loxP sites. (b) Plasmid map of the targeting vector following
ligation of two homologous recombination regions and floxed A1aA1b region into two MCSs.
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the 1.6kb PGK-Neo cassette in targeted loci can cause unexpected phenotypes in
knockout mice due to disruption of expression of neighboring genes within a locus
(Christine, 1996). To permit the removal of the resistance gene at any point in this
experiment, additional loxP sites were inserted, flanking the Beo resistance gene. Thus,
the fpgs targeting vector was designed for the deletion of the P1 promoter and exons
A1a and A1b in the fpgs gene in the mouse genome. The P1 promoter region, exons
A1a, A1b and the 5’ homologous recombination region recombination regions were
cloned into the MCS downstream of the floxed Beo gene, and the 3’ homologous
recombination region was cloned into the other MCS. In order to permit the deletion of
the upstream promoter and exons A1a and A1b in a time- and tissue-dependent manner,
another loxP site was inserted upstream, between the promoter and the 5’ homologous
recombination region (Fig. 6). These procedures are described briefly below and the
schematic diagram was shown in appendix A.
Since there was a paucity of useful restriction enzyme sites in the pKO Scrambler
vector, a smaller vector, the plasmid pBluescript II SK-, was used as an intermediate
vector to introduce the restriction enzyme sites needed for the insertion of a loxP
cassette at the desired site in the homologous region. The 5’ homology arm was
generated as follows:
(1) The 3.2kb HindIII - XhoI DNA fragment to be used as an upstream recombination
region was excised from genomic clone pGEMLZ-A1a plasmid, gel-purified and

47

ligated into the HindIII and XhoI sites of the pBluscript II SK- vector (Stratagene),
resulting in an intermediate plasmid pSK-A1aHIII-Xho.
(2) Two complementary DNA oligonucleotides (SalI-loxP-Xho-T 5’-TCG ACA TAA
CTT CGT ATA GCA TAC ATT ATA CGA ATT GAT C-3’ and SalI-loxP-Xho-B
5’-TCG AGA TAA CTT CGT ATA ATG TAT GCT ATA CGA AGT TAT G-3’)
Fig. 7) were designed to generate a loxP site cassette with SalI and XhoI ends, the
oligonucleotides were annealed and slowly cooled to room temperature to allow the
formation of double strand DNA fragment. These procedures are diagrammed in
Fig. 7. The double-stranded cassette was then inserted downstream of the 5’
recombination region of plasmid pSK-A1a HIII-XhoI from step (1). Ligation of
SalI (at the end of loxP cassette) to the XhoI site (at the end of 5’ recombination
region) abolished the internal XhoI site at the end of the 5’ recombination region,
and left a unique XhoI site at the end of the loxP cassette.
(3) Plasmid pGEMLZ-A1a was cut with XhoI and the 2.6 kb fragment containing the
exon A1a and A1b sequences was gel-purified (Fig. 5). The 3.3kb fragment
representing the 5’ recombination region with a loxP site was then cut out of pSKA1aHIII-Xho-Loxp with HindIII

and Xho I and gel-purified. The 2.6 kb

pGEMLZ-A1aXHoI fragment and the 3.3 kb fragment representing the 5’recombination region and loxP site were than moved into the HindIII – XhoI sites
of the pKO Scrambler NTKV 1901 targeting vector by three piece ligation to form
a intermediate targeting construct pKO2LX -A1a.
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Structure of a loxP site
Inverted repeat

SalI-loxp
--Xho-T
-T
SalI-loxp-Xho
I-B

Spacer

TCG AC ATAACTTCGTATA GCATACAT
G TATTGAAGCATAT CGTATGTA

Inverted repeat

TATACGAAGTTAT C
ATATGCTTCAATA
ATATGCTTCA
GAG CT

Fig 7. Sequence of a loxP site that was generated by two primers annealing with SalI and XhoI sticky ends. The loxP
sequence consists of two 13-bp inverted repeats flanking an 8-bp spacer region that determines the orientation of the
site. The sequence in a red box is a SalI recognition site, that in the black box is a XhoI recognition site.
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Fig 8. A. Schematic diagram showing the DNA enzyme restriction sites HindIII and BglII and the relative location
of the loxP sites and homologous recombination regions in the targeting vector. B. Constructed Targeting vector
was transformed into Stbl2 competent cells ( Invitrogen). Plasmid DNA from overnight bacterial cultures of
recombinant clones was purified, and analyzed by double digestion with Hind III and Bgl II and loaded on a 1%
agarose gel. Red arrows indicate the clones that were chosen for large DNA amplification, sequence analysis and
ES cell transfection.
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A 4.85kb XhoI – SpeI fragment, located in the intron region downstream of exon A1b
(Fig.5), was chosen as the 3’ homologous recombination region. The 3’ homology arm
was generated as follows:
(1) the 2.7kb XhoI – HindIII 3’-terminal fragment of plasmid pGEMLZ-A1a was
excised, gel-purified and cloned into the pBluescript II SK- vector ( Stratagen) to
form a intermediate plasmid pSK-XhoI-HindIII.
(2) The length of the 3’arm was increased by ligating a 2.2 kb HindIII-SpeI fragment
from plasmid pGEMLZ-Ex1 that was contiguous with the 2.7kb XhoI –HindIII
fragment in mouse genomic DNA (Fig. 5) into a resultant intermediate plasmid
pSK-XhoI-HIII to yield a 4.85 kb 3’ homology recombination region. This 4.85 kb
fragment was excised from pBluescrip with BotI and XhoI to introduce a unique
BotI site at the 3’ end of the downstream recombination region. The 4.85 kb
fragment with XhoI and BotI ends was then introduced into the intermediate
targeting construct pKO2LX -A1a which had been digested with SalI and BotI,
resulting in plasmid pKO2LX-FPGS-A1aA1b targeting vector (16.2 kb). The final
targeting vector pKO2LX-FPGS-A1aA1ab was then transformed into Stbl 2
chemically competent cells (Invitrogen). Plasmid DNA from overnight bacterial
cultures of recombinant clones was purified, and analyzed with restriction
enzymes HindIII and BglII digestion (Fig. 8). Clone number 10 and 12 were
chosen for large scale DNA amplification. The plasmids DNA were purified by
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Endofree Plasmid Maxi Kit (QIAGEN). The plasmid DNA sequence was again
confirmed by sequence analysis and the sequence-confirmed targeting vector was
transfected into mouse 129sv ES cells. This procedure for the introduction of the
3’-recombination region is diagrammed in Fig. 6.

Identification of homologous integration in ES clones
Mouse 129/sv derived ES cells were chosen for gene targeting, based on the
ability of ES cells from this stain to support germline transmission even after extensive
manipulation of the ES cells in culture (Simpon, 1997). A total of 30 µg of BotIlinearized pKO2lx FPGS-A1aA1b were electroporated into 129/sv ES cell (5 x 107
cells), and the ES cells were plated onto a feeder layer of primary embryonic fibroblasts.
After 10 days growth, G418 resistant clones were isolated and plated into two duplicate
96 well plates by Mrs. Herju Zhang in the Transgenic Core Facility at VCU.
ES clones that survive positive – negative selection are not all the desired
homologous recombinants. They may have survived drug selection because the
targeting vector was randomly integrated into the genome of the recipient ES cells with
the retention of the positive selection cassette and loss or mutation of the tk gene.
However, in the recipient ES cells where homologous recombination between the
targeting vector and the endogenous gene has occurred, the positive selection cassette
will be integrated into the target locus while the tk gene is lost and these cells will
survive both positive G418 and negative GANC selection (Fig. 9a).
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The clones harboring the desired homologous recombination event were then
identified by PCR analysis. Two sets of PCR primers were designed for this; 1.) Primers
+4309 and Neo 1B (Fig. 9a); The primer +4309 sequences were located at the 5’ intron
outside of the homologous recombination region contained in the targeting vector. The
anti-sense primer Neo 1B contained Beo gene specific sequence. Together, these
primers would amplify a 6.4kb DNA fragment if the genomic DNA of a cell contained
the properly inserted homologous recombinant fpgs sequence. 2.) Primer-15459 and
+ECB (Fig. 9a). The primer +ECB was targeting vector-specific sequence, located over
the unique restriction sites (EcoRI ClaI BamHI) downstream of the loxP3. The antisense primer -15459 was located in the third intron of fpgs gene sequence, outside of the
sequence used as a 3’ homologous region in the targeting vector. This set of primers
would amplify a 5.2 kb DNA fragment from the targeted fpgs genomic locus. The
genomic DNA of each G418 resistant clone was isolated from each well of 96 well
plates. PCR analysis was performed with primers +4309 and Neo1B, to identify clones
in which a correct 5’ homologous recombination event had occurred (Fig. 9A). Out of
192 clones, nine positive clones were identified by this first round of PCR screening
(Fig. 9B). These positive clones were further analyzed by a second round of PCR using
primer -15459 and +ECB to identify any of the clones with the correct 3’ homologous
recombination event. Any clones containing a correct integration event should give a
5.2 kb PCR product (Fig. 9A) in this second round of PCR. Five clones were clearly
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Fig. 9. PCR analysis of homologous recombinant targeted ES cell clones. (A) Schematic diagram showing the location of the
primer pairs used in the PCR analysis (black arrow. (B) Results of the PCR analysis using the primers 4309/Neo1B on one of
the 96 well plates. Alphabet number indicated the column number on the 94 well plates; the alphabet letter indicated the well
in each column. The positive clones were indicated with red letter. (c) PCR analysis using the primers +ECB/-10355 on the
clones that were identified positive from first round PCR analysis by primers 4309/Neo1B.
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identified to be inserted correctly by this second round of PCR (Fig. 9C). The clones
that were positive after the PCR screenings were subject to detailed sequence analysis.
Five independent recombinant ES cell clones (2.6% of the 192 total G418
resistance ES colonies originally isolated) were identified as potential homologous
recombinant candidates for further analysis. To ensure homologous recombination at
the FPGS locus, the PCR products were then gel purified and subjected to sequencing
analysis across the loxP1, loxP2, and loxP3 regions using fpgs primers noted in Fig. 10
Sequencing was conducted by the VCU Massey Cancer Center DNA Core facility.

Unintended homologous integration into the exon A1a/A1b region

In our conditional gene targeting, the critical exons were flanked with two loxP
sites in the targeting vector for deletion at a later step. This design was used to avoid the
potential lethality of genomic deletion during the development of the embryo. However,
it also carries a risk, since it results in the inclusion of an extra potential homologous
recombination region (Fig. 6). Hence, three fpgs intronic primers (FP1, 9860 and 10355) that represented sequence located next to the loxP sites were designed for
sequence analysis of the presence or absence of the three loxP sites, and this analysis
was the final step to confirm the correct homologous recombination. Genomic DNAs
were purified from the potential positive targeted ES cell clones, and the fpgs targeted
alleles were PCR amplified with the primers FPGS+4309 and Neo 1B, which were used
in the identification of 5’ homologous recombination event. The PCR product of 6.4 kb
55

a
PCR primer sequences for homologous recombination analysis in ES cell
Forward primer (5’ to 3’)
(bp)

Reverse primer (5’ to 3’)

FPGS+4309 CAGAAGTTTCTGCCACCTCCCAAT
+ECB
GATCGATCCTAGAGAATTCCTAGACCG

NEO 1B
FPGS-15459

product size

CATTCGACCACCAAGCGAAACATC
ATTGCATATCTGTGGAGGTCAGGG

6.4kb
5.2kb

Sequencing primers for loxPs analysis
FP1
TGAGTCAGTAGGCTCAGTGTGAGA
FPGS-9860 TCGCTTGTCTACCACGCACTGTAA
FPGS-10355 TGTTCAGGCATGTCACAGAGTCCA

loxP1
loxP2
loxP3
+ECB

b

BHI, ClaI, RI, SacII , Smal I
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Fig. 10. Analysis of prospective targeted ES cell clones. (a). The DNA sequence of PCR primers and the sequencing primers is
shown in the table. (b). Schematic diagram showing the location of the primer pairs used in the PCR analysis (black arrow) and
the primers used in the sequencing analysis of three loxPs (red arrow). (c). PCR re-analysis on ES clone 2D-6 with primer set
4309/Neo1B and +ECB/-10355 ( illustrated in a and b), the PCR products were on a 0.8% agarose gel. (d). The results of
sequence analysis that crossed the 3 loxP regions. Primers used for sequencing were FP1, 9860 and -1035. The ES clones
harboring all three loxP sites were indicated in red.
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were detected and purified from an agarose gel, and this DNA fragment was used for
sequencing analysis of loxP1 and loxP2 sites. Primer FP1 was used to sequence across
the loxP1 region and primer 9860 was used to sequence across the loxP2 region. Primer
FPGS-15459 and +ECB, which were used in the identification of the 3’ homologous
recombination events, were used to amplify a 5.2kb DNA band from the same genomic
DNA isolated from positive targeted ES clones. This 5.2kb product was then gel
purified and sequenced with primer -10355 to identify the existence of the loxP3 site.
Five out of six were sequenced successfully and identified to contain loxP3 sites. One
clone did not sequence well. Sequencing with primer 9860 indicated the presence of
loxP2 in all three clones that sequenced well. However, only three out of six ES clones
(2C-3, 2D-6 and 2G-9) were identified to contain loxP1 site, the other three ES clones
(2H-2, 2G-4 and 2E-7) were found to have wild type sequences instead of loxP1.
Clones 2C-3 and 2D-6 contained all three loxP sites, which were used for blastocyst
injection. LoxP1 and loxP3 were found in Clone 2G-9, but we failed to obtain good
sequence for the loxP2 (Fig. 10d). However, we had identified two clones that contain
all three loxP sites; hence we did not spend more time on clone 2G-9, which was
probably correct. The results of sequencing analysis, which across the loxP1, loxP2, and
loxP3 region on six potential positive targeted ES clones, indicated that 50% of our
targeted ES cell clones have lost the loxP1 site during recombination events. In these
targeted ES clones, the flanked A1aA1b region was used for homologous recombination
instead of our selected 5’ homologous recombination region (Fig. 10d).
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The position of insertion of targeting sequence in ES clones was also tested by
Southern blot analysis with SacII digested genomic DNAs using a probe extending
across A1a and A1b exons. A new SacII site was introduced in the targeting vector
next to the loxP3 site (Fig. 11A), so an 11 kb SacII fragment would be present in
homologous recombination allele in addition to the 18kb fragment from the unchanged
wild type allele using this probe (Fig. 11A). Because the introduced SacII site is locate
next to the loxP3 site, it would not be able to identify exactly where the upstream
homologous recombination event happened, and recombination either in the 5’
homologous recombination region or in the region meant to be floxed by loxP1 and
loxP2 would produce the same SacII digestion pattern. This was clearly showed in Fig.
11B. Both endogenous (18kb) and targeted (11kb) alleles were detected on the ES
clones loaded in lane 2,3,4 and 5. However, only the ES clones loaded in lane 4 (2C-3)
and 5 (2D-6) contain all three loxP sites. Hence to identify correctly targeted ES cells
clones, the sequence analysis of all three loxP sites is still a necessary step for our
designed targeting vector.

Cre excision in targeted ES cell
The expression of the neomycin phosphotransferase gene driven by the
phosphoglycerate kinase I promoter (PGK-Beo) is widely used as a selectable marker
for homologous recombination in ES cells. Previous studies have shows that retention
of the PGK-Beo selection cassette in targeted loci may yield unexpected phenotypes in
knockout mice due to the altered expression of neighboring genes (Olson, 1996). To
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Fig 11. Southern Analysis of Homologous recombination. A: The diagram shows the SacII sites at endogenous fpgs locus and
targeted locus with the A1aA1b probe. The Targeted ES cells have a 11 kb SacII –digested band, in addition to an 18 kb wild type
band, following hybridization with the A1aA1b probe. B: Southern blot analysis of the ES cell clones. Clone 1-wild-type ES
clones, clone 2, 3,4,5 were targeted ES cells, but clone 2 and 3 lost loxp1 site. ( the genomic DNA were isolated from low density
cells, so the concentration is much lower in Lane 1,2,3 )
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eliminate the potential interference of the PGK-Beo, the pCMV-Cre plasmid** was
introduced into the correctly targeted ES clone 2D-6 by electroporation. The expression
of Cre recombinase in ES cell that contain targeted loci with loxP sites will result in
three possible Cre-mediated deletions (Fig. 12B): 1.) The Cre recombinase catalyzed
recombination between the first and the third loxP sites resulting in deletion of upstream
promoter P1 and A1a/A1b exons and the Beo cassette (complete deletion). This ES cell
would be useful for generation of P1 null mice (-/-). 2.) The Cre recombinase catalyzed
recombination between the second and the third loxP sites; this will result in a deletion
of PGK- Beo cassette, leaving two loxP sites flanking upstream promoter P1, A1a and
A1b exons. This ES clone could be used to generate conditional knockout mice. 3.) In
the last alternative, the Cre recombination could catalyze recombination between the
first two loxP sites, resulting in the deletion of exons A1a and A1b and retention of the
Beo cassette. The cells with the complete deletion and the conditional allele are not
viable under G418 selection, allowing identification of the useful alleles (Fig. 12).
After transfection, the cells were cultured for two days and spread into 100mm
dishes by serial dilution (500-2000 cells per dish) to form colonies. About twenty-four
clones were picked after one-two week culture and seeded in duplicate plates. One set
was grown in selection media with 180 ug /ml G418. (This was done by Mrs. Herju
Zhang in the Transgenic Core Facility at VCU). The duplicate plate was used to expand
the non-surviving clones from selection foe genotyping of targeted allele by PCR.
Fourteen out of twenty-four G418 sensitive clones contained Cre mediated deletion
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A1a A1b

HIII
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Endogenous Locus
( FPGS )

tk

Targeting vector

Neo
loxP1

Targeted locus:

loxP2

loxP3

Neo
loxP1

loxP2

loxP3

CRE recombination

B

Excision between loxp2 and loxp3
(conditional knockout locus)
loxP1

Excision between loxp1 and loxp2
(Neo allele)

loxP2,3
loxP2/3

Neo
loxP1/2

loxP3

Excision between loxp1 and loxp3
(Complete deletion locus)
loxP1/3
loxP1,3

Fig 12. Gene targeting in ES cell and Cre mediated deletion of the A1aA1b region and the selection marker. (A)
Schematic diagram showing homologous recombination of the targeting vector with endogenous fpgs locus in ES
cells. (B) Cre-mediated recombination products. Recombination between loxP2-loxP3 sites (large filled triangles)
that flanked the Beo marker, leads to the production of a conditional knockout locus. Recombination between loxP1
and loxP3 lead to the deletion of the upstream promoter and A1aA1b exon, leaving one loxP1,3 site in the genome,
a complete deletion allele. Recombination between loxP1 and loxP2 would delete P1 and exons A1a and A1b, but
would leave behind a Beo casstte.
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alleles of these six ES clones contained the alleles that recombined between loxP2 and
loxP3 (Fig. 13), and eight clones had recombined between loxp1 and loxP3 (complete
deletion). Hence, transient expression of Cre recombinase in targeted ES cell 2D-6 was
sufficient to induce recombination in more than 50% of the cell clones studied. The
G418 sensitive ES cell clone #10 contained a complete A1aA1b knockout allele (KO-10)
and clone #18 contained a loxP flanked A1aA1b allele (conditional knockout CKO-18),
these clones were chosen for C57BL/6 blastocyst injection to create chimeric mice.

Generation of homozygous knockout mice
An ES cell clone that had undergone correct homologous recombination and Credeletion of the Beo gene (conditional knockout clone #18, CKO-18) and a second
targeted ES cell clone with Cre-mediated complete deletion of P1 promoter and exons
A1a and A1b (knockout clone #10, KO-10) were injected into C57BL/6 blastocysts by
Mrs. Herju Zhang of the VCU-transgenic core facility.

Injected blastocysts were

transferred into three pseudo-pregnant mice. The chimeric nature of resulting offspring
was determined by coat color. Three KO-10 chimera males and nine CKO-18 chimera
males were identified that had 50% - 95% agouti coat color. These males were bred to
C57BL/6 females to obtain germline transmission of the targeted allele.

** Note that the pCMV-Cre plasmid contains a neo-resistance cassette, so that any subclone that
stably integrated pCMV-Cre could be discarded during cellular screening for Neo-resistant
subclones.
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Conditional Knock out allele
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Fig 13. In-vitro Cre recombination. A, Diagram of alleles in targeted ES cell that resulted from CreCremediated deletion of the A1aA1b Exons and PGK-Beo cassettes. Arrows indicate the location of PCR
primers ( FP1/-ECB) and the size of the PCR product. B, the results of PCR analysis using the primer set
FP1/-ECB (illustrated in A) in order to determine Cre recombination events. PCR products were analyzed
in a 1% agarose gel.
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One KO-10 chimera male (#3) was sterile (Table 2). The other two chimeras, both of
which contained higher percentage of agouti coat color, produced forty-three pups, 75%
of these pups had agouti coat color. Forty-one pups from CKO18 chimera were all
agouti. The agouti coat color from the 129/sv ES cell is dominant over C57BL/6 black
coat color, which facilitates the identification of pups derived from the 129/sv ES cells.
Based on the results of PCR genotyping of tail DNA (see Methods and Fig 10) of each
animal (Table 2), we found that half of the F1 agouti offspring were heterozygous for
the targeted alleles (complete knock out or conditional knock out). Heterozygous F1
mice (+/-), which carried the FPGS-P1 deletion allele, were mated to generate
homozygous knockout F2 mouse with a mixed 129sv/C57BL/6 genetic background.
Seventy-seven F2 mice resulting from heterozygous F1 intercrosses were genotyped
and assigned to one of the three possible categories: wild type (+/+), heterozygous (+/-)
and homozygous mutant (-/-) mice. The genotypic analysis confirmed the presence of
complete knockout pups, as well as wild type and heterozygous individuals. The ratio of
homozygous: heterozygous : wild-type mice agreed with 1:2:1 Mendelian frequency
(Table 3). No obvious phenotype differences were observed between animals with the
three genotypes. Fewer females were obtained than expected in both in the homozygous
KO genotype and wild-type genotypes (Table 3). This first data set suggested that the
targeted deletion of the FPGS P1 promoter was compatible with an apparently normal
embryonic development, an observation that surprised us. The homozygous P1
knockout (-/-) mouse exhibited an apparently normal phenotype, showing no gross
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Table 2 Chimera offspring germline transmission summaries
Mouse strain

Cell Line

Chimera

Complete
P1-A1aA1b
knockout

KO-10

3 Agouti male

Conditional
knockout

CKO-18

Total Pups

Agouti Pups

Percentage

Genotype
A1aA1b

KO10-1 M 95% agouti

18

9

50%

3 +/-

KO10-2 M 70% agouti

25

25

100%

12 +/- 13 +/+

KO10-3 M 50% agouti

21

0

0

CKO18-2 100% agouti

15

15

100%

2 +/c

7 +/+

CKO18-9 98% agouti

18

18

100%

5 +/c

9 +/+

CKO18-10 75% agouti

8

8

100%

3 +/c

8 +/+

6 +/+

9 agouti male
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morphological defects, and were not distinguishable from their wild type or
heterozygous littermate. Moreover, both male and female mutant mice were fertile and
both were used to establish subsequent homozygous mutant mouse colonies from F2
individual of the two mixed genetic background -129sv/C57BL/6 (Table 4, 5).

Breeding targeted alleles into the C57BL/6 strain.
Our targeted ES cell lines were derived from the 129/sv strain of mice. Many
studies have shown that the 129/sv strain has significant biological limitations that
could interfere with phenotypic analysis of a targeted allele, because 129 strains are
actually a diverse and complex family of sub-strains (Crawlel, et al. 1997). C57BL/6
mice breed well and are commonly used in the production of transgenic mice. In order
to obtain a C57BL/6 congenic knock-out strain, the heterozygous F1 mice were
backcrossed to C57BL/6 for six generations before being interbred to produce the
homozygous P1-A1aA1b knockout and wild-type littermate mice used in this study.
Two sets of oligonucleotide primers were designed for PCR analysis to distinguish
wild-type, heterozygous, and homozygous mice of complete P1-A1aA1b knockout (Fig.
14A, 15). Primer FPGS 9047 and FPGS -9322 were located in the exons A1a and A1b
and are designed to detect the existance of wild-type alleles. PCR amplification on the
genomic DNA that was purified from the wild-type or heterozygous KO mouse with
primers 9047-9322 would produce a 275 bp DNA band (Table 1 and Fig. 14, 15).
Targeting vector specific primer “-ECB” and fpgs intronic primer FP1, were designed to

66

Table 3. Genotype of C57BL/6 backcross progeny –KBF6
Genetic
background
C57BL/6

Heterozygous
Knockout
+/-

Wild-type

Total

Mendelian
frequency

Total
expected

78

78

156

1:1

Total
observed

78

78

156

1:1

Male
observed

44

43

78

1:1

Female
observed

34

35

78

1:1

+/+

Table 4. Genotype of progeny of F1 or F6 heterozygous intercrosses
Genetic background

Wild-type

Mendelian
frequency

Homozygous
knockout
-/-

Total

+/+

Heterozygous
Knockout
+/-

(C57BL/6)F6 -2KBF1-2
expected

37.25

74.5

37.25

149

1:2:1

Total
observed

47

67

32

149

1 : 1.4 : 0.7

Male
observed

24

33

19

76

1 : 1.4 : 0.8

Female
observed

23

34

13

70

1 : 1.5 : 0.5

(129sv/C57BL6)F1-2KOF1
Expected

18

35

18

72

1:2:1

Total
observed

19

34

19

72

1 : 1.8 : 1

male
observed

13

16

12

41

1 : 1.2 : 0.9

Female
observed

6

18

7

31

1 : 3 : 1.1
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+/+ : +/- : -/-

amplify a 175 bp DNA band from the mouse genomic DNA that contain the P1A1aA1b knockout allele.
Out of 156 KBF6 (KO #10 germline backcrossing into the C57BL6 strain for six
generations) mice, 78 were male and 78 were female, 44 male and 34 female mice
contained the heterozygous P1 KO allele (Table 3). The ratio of mice with genotype
+/+ to mice with genotype +/- was 1:1, and the ratio of male to female with genotype
+/- was 1.2:1. This gender distribution was found to differ from Mendelian transmission
of genotypes from which an equal number of males and females were expected.
However, when compared with wild type mice and confirmed with χ2 value (= 1.05) the
deviation was not statistical significant P > 0.05.

Phenotype of complete knockout mice
Crossing of heterozygous mice produced viable homozygous offspring in both
the C57BL/6 (Table 5) and 129SV/C57BL/6 mixed backgrounds (Table 4). Breeder
pairs of fpgs heterozygous males and females generated normal litter sizes (average 8
pups/litter) at the expected frequency (every 3-4 weeks) (Table 4). One hundred forty
nine pups were produced from intercrossing of heterozygous mice with C57BL/6
background. The genotyping analyses of these pups confirmed the presence of
homozygous knockout mice (-/-), as well as heterozygous mutant (+/-) and wild type
(+/+) at the ratio of 1:1.4:0.7, which was different from the expected Mendelian ratio of
1:2:1 (Table 4). In addition, the ratio of male and female mice did not deviate from
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Table 1 PCR primer sequences for the targeting allele analysis in ES clones
Forward primer (5’ to 3’)

Reverse primer (5’ to 3’)

product size (bp)
CDKO
KO

FPGS+4309 CAGAAGTTTCTGCCACCTCCCAAT
NEO 1B
+ECB
GATCGATCCTAGAGAATTCCTAGACCG FPGS-15459
FPGS-9047 TGCGAACCTCTCAGGTAAACACTC
FPGS-9322

CATTCGACCACCAAGCGAAACATC 6400 bp
ATTGCATATCTGTGGAGGTCAGGG 6400 bp
CCTGAAAGGAGGCAGTCTTAGCTT
275 bp

FP1
TGAGTCAGTAGGCTCAGTGTGAGA
FPGS-9860 TCGCTTGTCTACCACGCACTGTAA

GCGGTCTAGGAATTCTCTAGGATCG 4664 bp 175 bp
TGTTCAGGCATGTCACAGAGTCCA 2250 bp 576 bp

4309

FP1

-ECB
FPGS-10355

9047 9860

+ECB

Neo

-9322

NeoB -ECB -10355

-15459

Fig14. Schematic diagram showing the location of the primer pairs (black arrow) used in PCR for mouse fpgs
genotyping. The sequences of primers were shown in the table1. CDKO: The size of the PCR product generated from a
conditional knockout allele. KO: the size of the PCR product generated from complete P1 Aa1aA1b knockout allele.
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Ex1

A

Ex2 Ex3

A1aA1b
9047

Ex1

Ex2 Ex3

FP1

-ECB
-9322

WT allele

KO allele

B

2KBF1- 1 2

WT allele
KO allele

3

4

IKB plus bp

5

6

7 8

9 10 11 12 13 14 15 16 17 18 19 20 21

500
400
300
200
100

Fig 15. Genotyping of C57BL/6 backcrossing offspring. (A) Structure of the wild-type and knockout fpgs alleles. The
start sites of the two transcript fpgs are shown by the dotted arrow. The primers used in the analysis are indicated as
short arrows. (B) PCR genotyping of mouse tail DNA. The wild-type allele produces a band at approximately 295bp with
primers 9047 and 9322, while the mutant allele produces a band at approximately 175bp with primers FP1 and -ECB.
The wild-type (lanes 3, 15, 18, 19) mice show only one band at 295bp, the heterozygous mice (lanes 2,4,5,6,7,8,
11,13,14,16, 20, 21) show both 295- and 175-bp bands and the homozygous KO mice ( lanes 1,9,10,14,17) show only
one band at 175 bp.
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expected for the homozygous -/- mice. Homozygous (-/-) males and females
were obtained at the ratio of 1.4:1, which was not statistically significant different from
the expected 1:1, and also confirmed by χ2 value (=1.12) P > 0.05. No differences were
observed between animals derived from two genetic backgrounds, 129sv/ C57BL/6 mix
and C57BL/ 6 genetic backgrounds in terms of sex ratios (Table 4). N6F1 homozygous
(-/-) mice with C75BL/6 background, developed normally and do not showed any
obvious alteration in morphology. There are no differences with mice body length or
body weight between knockout mice and wild-type mice (Fig. 16). Moreover, both male
and female 2KBF1 -/- mice were fertile and was used to produce subsequent
homozygous knockout mouse colonies (2KBF2). The absence of apparent overt
phenotypic differences in homozygous KO mice was further investigated. The growth
curves of 2KBF1 knockout mice vs. wild -type litter mates were analyzed from the
onset of weaning age (4 weeks old), fed either with normal diet (1300 ug folate /kg diet,
Test Diet) or low folate diet (63 ug folate/kg diet, Test Diet). All three genotypes of
mice (+/+, +/-, and -/-) were observed for growth, each group contained at least six mice,
that were produced from several independent litters. Body weight was recorded twice
a week from 4 weeks of age to 14 weeks of age. Body weight increased with aging and
was higher in males than in females. No significant weight differences were detected
between the mice fed with normal diet and low folate diet (Fig 19, 20). All genotypes
(+/+, +/-, -/-) appeared to grow and gain weight at similar rates, and follow comparable
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Table 5. Homozygous KO mouse reproduction and lifespan
Filial
generation
number

Number of
Mouse
produced

Number of
female

Number of
male

F1 +/-

10

6

2

2KOF2

19

7

12

11

2KOF3

39

15

24

13

5

2KOF4

62

28

33

9

9

2KOF5

23

10

16

7

4

2KOF6

10

7

2

4

2

2KOF7

5

2

3

3

1

TOTAL

158

69

90

72

Time
observed

Number of
litter
produced

21

A

B

WT +/+
KO (-/-)
Mouse age: 2 months

C

WT +/+
KO (-/-)
Mouse age: 7 months

WT +/+
KO (-/-)
Mouse age: 2 months

E

D

P1-A1aA1b KO (-/-) mouse
41g

P1-A1aA1b KO (-/-) mouse
31g

Fig16. Comparison of homozygous P1 KO mice with its wild-type litter mate. (A). 8 weeks old adult male KO and WT mouse. (B). 7
month old male KO mice and WT male mice. (C) 8 weeks old adult female KO mice and WT mice. Mice in A,B and C were under
anesthesia when the pictures were taken for better comparison. (D,E) KO mice with out anesthesia.
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growth curves. Differences in weight between wild type and KO mice of similar age
were not statistically significant. (Fig. 17, 18) More detailed analysis over extended
periods of time is currently underway to uncover any potentially subtle differences in
A1aA1b knockout versus wild type mice.

Effect of P1 deletion on fpgs gene expression in mouse liver

To define the effects of deletion of P1 and exons A1a and A1b on mouse liver
fpgs gene expression, total RNA was extracted from adult liver from fpgs-P1
homozygous knockout (-/-), heterozygous -knoockout (+/-) and wild-type (+/+) mice,
and mRNA was reverse-transcribed into cDNA using an oligo dT primer (Invitrogen).
Real-time reverse transcription polymerase chain reaction (RT-qPCR) experiments,
based on SYBR Green detection, were conducted to measure the expression of mRNA
transcript levels from fpgs promoter P1 and P2. Two sets of fpgs specific primers were
designed to detect the expression level of fpgs mRNA species; 1.) Primer A1aA1b-A
was located in the sequences of exon A1a (5’-TGT GCA CAG GAT GGA AAT GCG
AAC C-3’), and its anti-sense primer –Ex3a (5’- TGT TTA GCC GGT TCA AGT CCT
CCA – 3’) was located in exon 3. Together, these primers would amplify a 340bp
cDNA fragment from P1 fpgs mRNA species. 2.) Primer Ex1 (5’-CTA GCT TGC GGT
GGC ATT AAG ACT- 3’) was located in the sequence of exon 1(Fig. 21), which was
used in the transcript made from P2. Primer Ex1 and anti-sense primer -Ex3a amplify a
343 bp cDNA fragment from P2 fpgs mRNA species. The real time PCR results were
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Female mice growth curve
KO vs. WT

Body Weight (g)

19
18

+/+ F

17
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8

8.42

Mouse Age (w eek)

Fig17. Body weight increase in weaning mice of wild-type and KO female mice. Each group contain six weaning age mice
with same genetic background ( C57BL/6 F6). The body weight were measured twice a week start at weaning age (4 weeks
old). The wild-type mice show in close diamond and A1aA1b KO mice show in square.
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Male Mouse Growth Curve
KO vs. WT
26
-/- M

24

+/+ M

Body Weight (g)
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Fig. 18. Body weight increase in weaning mice of wild-type and KO male mice. Each group contain six weaning age mice with same
genetic background ( C57BL/6 F6). The body weight were measured twice a week start at weaning age (4 weeks old). The wild-type mice
show in close square and A1aA1b KO mice show in triangle.
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Female mice growth curve
Normal diet vs. low folate diet
19
18
Body Weight (g)

17
16
15

+/+ F

14

-/- F

13

+/+ 63ug/kg
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-/- 63ug/kg
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10.4

mouse age (week)

Fig. 19. Comparison of female mice growth pattern of wild-type and KO that fed with the diet contained either 1300 ug/kg or
63 ug/kg folate. Each group contain six weaning age mice with same genetic background ( C57BL/6 F6). The body weight
were measured twice a week start at weaning age (4 weeks old). The genotype of mice and folate contains of each curve
represent are indicated in the box above.
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Male growth curve
normal diet vs. low folate diet
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24
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Fig. 20. Comparison of male mice growth pattern of wild-type and KO that fed with diet contained either 1300 ug/kg or 63 ug/kg
folate. Each group contain six weaning age mice with same genetic background ( C57BL/6 F6). The body weight were measured
twice a week start at weaning age (4 weeks old). The genotype
78 of mice and folate contains of each curve represent are indicated
in the box above.

normalized to the mouse actin gene to control for the cDNA loading in the reaction and
calculated as 2∆Ct method using reference gene (see Method), which allows us to
directly compare quantitative data from two separate experiments. All qPCR reactions
were in duplicate or triplicate. To make the comparison among each qPCR run reliable,
the analysis of gene expression of each genotype were done with RNA from six
individual mice. Our results revealed asignificant changes in fpgs gene expression
following the deletion of upstream promoter P1 and exons A1a and A1b. As expected,
P1 transcription was not detectable in homozygous P1 knockout mouse liver, and was
2.4 fold reduced in heterozygous knockout mouse liver compared to the expression in
RNA from livers of wild-type mice (Fig. 22). This result indicated that the two fpgs
alleles are equally expressed in the mouse liver. Deletion of one allele will reduce the
total amount of gene transcription by about ½ if both alleles are expressed
independently. In contrast, after deletion of upstream promoter P1 and exons A1a and
A1b, the expression of the P2 transcript was up-regulated in mouse liver. As shown in
Fig. 23, the P2 transcription level increased 4.6 fold in homozygous P1 knockout mice
and 3 fold in heterozygous mice. The relative expression levels of P1 to P2 transcription
in mouse liver were compared in Fig. 24; RT-qPCR data analysis indicated a 480 fold
higher P1 transcript level than P2 transcript level in wild-type mouse liver. Interestingly,
in wild-type mouse liver there was a 100 fold higher fpgs transcript level, almost all
from P1, than the transcript level in the KO mouse, which only expressed fpgs mRNA
from P2 (Fig 24,).
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PCR primer sequences for the targeting allele analysis in ES clones
Forward primer (5’ to 3’)

Reverse primer (5’ to 3’)

product size (bp)

A1aA1b-A 5’-TGTGCACAGGATGGAAATGCGAAC C-3’ -Ex3a 5’- TGTTTAGCCGGTTCAAGTCCTCCA – 3’

340

Ex1

5’-CTAGCTTGCGGTGGCATTAAG ACT-3’

-Ex3a 5’- TGTTTAGCCGGTTCAAGTCCTCCA – 3’

343

Ex3F

5’-TCATGTCACTGGGACCAAAGGGAA-3’

Ex6R 5’-AGACATGGCTGTCGTCCTTGAACT-3’

218

P1 transcript

A1aA1b-A

P2 transcript

Ex1
Ex3F

-Ex3a

Exon A1a A1b

1

2 3

Ex6R

4

5 6 7 8

9

10 11

121314

15

Fig. 21. Schematic diagram showing the location of the primer pairs (black arrow) used in RT-qPCR for fpgs gene expression
analysis. The sequences of primers and size of PCR product were show in the table1above.
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Fig 22. Relative fpgs P1 expression change after deletion of upstream promoter P1 and exons A1aA1a in mouse liver determined
by real-time PCR. The fpgs transcript from P1 was completely abolished in homozygous A1aA1b knockout (-/-) mice liver, and
the P1 transcription level was 2.5 fold reduced in heterozygous knockout (+/-) mice liver compared to wild type (WT, +/+). Bars
show the mean ±STD from six mice ( 3male + 3 female) livers.
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Q-PCR has a sensitivity that makes it possible to robustly detect and quantify low-level
gene expression from RNA in tissue. However, qPCR analysis of a gene expression is
based on the PCR amplification by the specific primer set, so that potential bias may be
introduced when comparing data across primer sets by differences in template
preference, length and variations of PCR amplification efficiency. To make the
comparison of the relative abundance of the mRNAs for the two fpgs isoforms reliable,
primers Ex3F (5’-TCA TGT CAC TGG GAC CAA AGG GAA-3’) and Ex6R (5’-AGA
CAT GGC TGT CGT CCT TGA ACT-3’) (Fig. 21) were designed and used to amplify
a 218bp cDNA fragment from exon3 to exon 6 of fpgs cDNA. Since both isoforms of
fpgs mRNA sequences differ only on the N-terminal exon, and have identical sequences
after exon 2, the fpgs mRNA transcripts detected by Ex3F and Ex6R primer would
represent the total fpgs transcripts in a tissue. It was used as an internal control in RTqPCR gene expression analysis. The relative expression levels of P1 to P2 detected by
Ex3F-Ex6R primers largely agreed with the previous data determined with A1aA1b-A
and Ex1 primers; the total mRNA for fpgs was much lower in KO than in wild type
liver, but the ratio was only 15-fold different. This result confirmed that the fpgs P1
transcript in wild-type mouse liver was between 15-fold to 100 fold higher than the P2
transcript in knockout mouse liver (Fig. 25).
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Fig 23. Relative fpgs Ex1 isoform expression upon deletion of P1 in mouse liver determined by realtime PCR. Deletion of
upstream promoter P1 and exons A1a and A1b up-regulated the downstream P2 transcription by 4.6 fold in KO (-/-)mouse liver,
and 3 fold increase in heterozygous A1aA1b KO (+/-) mice liver. Bars show the mean ±STD from six mice ( 3male + 3 female)
livers.
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Fig. 24. Comparison of fpgs P1 and P2 expression in mouse liver. The fpgs P2 transcript level were 99 fold lower in P1
knockout mice (-/-) compare to fpgs P1 transcript in wild type mouse (+/+) liver. Bars show the mean ±STD from six
mice ( 3male + 3 female) liver.
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Effect of P1 deletion on fpgs gene expression in mouse kidney
The results of RNA Protection Assay (RPA) experiments from previous studies in this
laboratory by Fiona Turner indicated that mouse kidney expresses transcripts from both
P1 and P2 promoters in a ratio of about 6-10 to 1 (Turner and Moran 1999). To define
the effect of P1 deletion on fpgs gene expression from P2 in mouse kidney, real time
qPCR analysis were performed on the cDNA reverse-transcribed from the total RNA
isolated from mouse kidney from mice with different genotypes.

Notably, the

expression of P1 mRNA in the kidney was abolished in the homozygous P1 KO mice
kidney, and was reduced by half in heterozygous mouse kidney compared to the level
expressed in the wild-type kidney. The decrease in P1 expression in heterozygous
mouse kidney resulted from the deletion of one of two fpgs allele (Fig. 26) and was
expected. In contrast, the fpgs transcripts originating at P2 were up-regulated 1.5 fold in
both heterozygous and homozygous P1 knockout mouse compared to kidney from wildtype mice (Fig. 27). The ratio of transcripts from P1 and P2 level was calculated from
qPCR analysis data. Comparing P1 and P2 expression in kidneys from wild type mice,
qPCR suggested that P2 transcripts were 28-fold lower than P1 transcripts. P1
expression in wild-type mouse kidney was 18 fold higher than P2 expression in the
homozygous P1 knockout mouse kidney (Fig. 28). The 18-fold difference of P1 and P2
expression were also detected by qPCR with internal gene expression primers Ex3F and
Ex6R. (Fig 29)
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Fig. 25. Comparison of fpgs mRNA expression in mouse liver. The expression level of fpgs P1 transcript in wild-type
(+/+) mouse liver and P2 transcripts in P1 KO mouse (-/-) liver were compared with total fpgs transcript level Ex3-6,
exons used by both fpgs species, P1 and P2. Bars show the mean ±STD of duplicated RT-qPCR analysis of 1 female .
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Fig. 26. Relative fpgs P1 expression change after deletion of upstream promoter P1 and exons A1aA1a in mouse kidney
determined by real-time PCR. The fpgs transcript from P1 was completely abolished in homozygous A1aA1b knockout (-/-)
mice kidney, and the P1 transcription level was 2.5 fold reduced in heterozygous knockout (+/-) mice kidney compared to
wild type (WT, +/+). Bars show the mean ±STD from six mice ( 3male + 3 female) kidney.
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Fig. 27. Relative fpgs P2 expression upon deletion of P1 in mouse kidney determined by realtime qPCR. Deletion of upstream
promoter P1 and exons A1a and A1b up-regulated the downstream P2 transcription by 0.47 fold in KO (-/-)mousekidney, and
0.66 fold increase in heterozygous A1aA1b KO (+/-) mice kidney. Bars show the mean ±STD from six mice ( 3male + 3
female) kidney.
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Fig 28. comparison of fpgs P1 and P2 expression in mouse kidney. The fpgs P2 isoform expression in A1aA1b knockout mice
were 17.8 fold lower compared to fpgs A1aA1b isoform expressed in wild type mouse kidney. Bars show the mean ±STD from
six mice ( 3male + 3 female) kidneys.
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Comparison of fpgs gene expression in male vs. female mouse
To get further insight into the implication of the real time qPCR data, RT-qPCR
analysis was applied to groups of male and female mice. The expression of P1 mRNA
in wild-type mouse liver is 30% higher in male than in female (Fig. 30), but, in
heterozygous P1 knockout mice, P1 transcription level was not significantly different
between male and female (Fig. 30). In contrast, the P2 transcription level in
homozygous knockout male mice liver is 78% higher than in homozygous knockout
female mice liver (Fig. 31). Transcription from P2 in heterozygous mice liver is 50%
higher in males than in females, and in wild-type mice liver is 30% higher in males than
in females (Fig 31).
The gender differences in fpgs gene expression were also observed in mouse kidney.
The expression of P1 mRNA in heterozygous KO mice kidney is 78% higher in male
than female, but no differences were observed in wild-type mice (Fig 32). P2 mRNA
expression level in homozygous knockout mice kidney is 78% higher in male than in
female. However, in both heterozygous knockout mice and wild type mice kidney, this
difference is not as significant as in homozygous knockout mice (Fig 33). In conclusion,
the overall expression of fpgs in both liver and kidney was substantially higher in male
mice than in female mice.
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Fig 29 Comparison of fpgs mRNA expression in mouse kidney. The level of fpgs P1 transcript expressed in wild-type mouse
kidney and P2 transcripts expressed in P1 KO mouse kidney were compared by qPCR analysis, and the total fpgs transcription
level using Ex3-6 primer (exon 3-6 were common used by two fpgs species, P1 and P2) were also compared by real time qPCR.
Bars show the mean ±STD of duplicated RT-qPCR analysis of 1 female (2KBF1).
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Fig. 30. Comparison of relative fpgs P1 expression in male and female mice liver of three A1aA1b genotypes by real-time
qPCR. the P1 transcription level was 0.33 fold higher in wild-type male than female mice, 0.12 fold higher in
heterozygous knockout (+/-) male than female mice. Bars show the mean ±STD from 3 mice ( 3male or 3 female) liver.
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Fig. 31. Comparison of relative fpgs P2 expression in male and female mice liver of three A1aA1b genotypes by real-time qPCR.
the P2 transcription level was 0.33 fold higher in wild-type male than female mice, 0.45 fold higher in heterozygous knockout
(+/-) male mice liver than female, and was 0.77 fold higher in homozygous KO male mice liver than female. Bars show the
mean ±STD from 3 mice ( 3male or 3 female) kidney.
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Fig. 32. Comparison of relative fpgs P1 expression in male and female mice kidney of three A1aA1b genotypes and
determined by real-time qPCR. the P1 transcription level was same in wild-type male than female mice, 0.73 fold higher in
heterozygous knockout (+/-) male than female mice. Bars show the mean ±STD from 3 mice ( 3male or 3 female) kidney.
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Fig. 33. Comparison of relative fpgs P2 expression in male and female mice kidney of three A1aA1b genotypes by real-time
qPCR. the P2 transcription level was 0.17 fold higher in wild-type male than female mice, 0.11 fold increase in heterozygous
knockout (+/-) male mice kidney than female, and was 0.77 fold higher in KO male mouse kidney than female. Bars show the
mean ±STD from 3 mice ( 3male or 3 female) kidney.
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Effect of fpgs P1 promoter deletion on liver FPGS enzyme activity
The level of fpgs gene expression was dramatically decreased in homozygous
knockout mouse liver and kidney compared to the wild-type mouse. However, the mice
had survived with this major modification. To determine whether deletion of P1 and
activation of P2 would produce sufficient functional FPGS for survival, FPGS enzyme
activity was measured with an assay developed in this laboratory.

The mouse livers

were perfused with 1x PBS and a 100,000xg supernatant produced from livers. The
glutamic acid present in the liver tissue was removed with a Sephadex G-50 spin
column, and the supernatant fraction of liver homogenate was then used as a source of
FPGS. About 13 ug of crude lysate was incubated with a saturated amount of H4PteGlu
and H3-glutamic acid substrates. The C57BL/6 mouse liver crude lysate was also
included in the experiment and use as the assay control. Our result indicated that the
FPGS enzyme activity in our produced wild-type littermates mouse is similar to its
breeding strain C57BL/6, and the FPGS enzyme activity was about 3 fold lower in P1
homozygous knockout mouse liver compared to wild type mouse liver (Fig 34) and 2
fold lower in the heterozygous knockout mice. But, the survival and normal growing
curve of the knockout mice indicated that these amounts of FPGS enzyme were enough
for the survival of the mouse.
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Fig 34. Comparison of liver FPGS enzyme activity in three genotypes (+/+, +/- and -/-) . FPGS enzyme activity
was determined by micro-assay with 13ug liver crude lysate protein and saturating H4PteGlu and L-[H3]Glutamic acid substrate. The mouse genotype were indicated in the box. Crude lysate of C57BL/6 liver were
used as wild type control.
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CHAPTER 4: Discussion
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Gene targeting is the introduction of a modification at a specific location in the
genome by homologous recombination. The frequency of homologous recombination is
a linear function of length of homology between DNAs (Fujitani,1995). Many research
studies have shown the direct relationship between homology length and targeting
frequency, and found that homology of only 1 kb is sufficient (Kamisugi, 2005). In the
conventional gene targeting method, the vector contains two regions of homology to the
target gene located on either side of a positive selectable marker replacing the
intermediate exon sequence in between. In our conditional gene targeting, the vector
was designed similar to the conventional gene targeting strategy, but, instead of deletion
of promoter and exons during construction of a targeting vector, the critical promoter P1
and exons A1a and A1b were flanked with two loxP sites in the targeting vector for
deletion at a later step. This is a very powerful approach for potentially lethal genomic
deletion. However, it also carries a risk, since it results in the inclusion of an extra 2.6
kb potential homologous recombination region. The results of sequencing analysis
across the loxP1, loxP2, and loxP3 region on six potential positive targeted ES clones
indicated that 50% of our targeted ES cell clones lost loxP1 site during recombination
events. In these targeted ES clones, the flanked region (P1, A1a and A1b) was used for
homologous recombination instead of our selected 5’ homologous recombination region
(Fig. 10d). The competition between the designed homologous recombination region
and the flanking gene sequences for homologous recombination was obvious in
retrospect, but initially was an unpleasant surprise. Over 1kb long of flanking target
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sequence in the condition knockout targeting vector construct certainly created a
potential risk for an unwanted homologous recombination event, resulting in the loss of
LoxP1(Fig 10). To eliminate such incidence the detailed sequencing analysis across all
three loxP sites of targeted locus in potential targeting ES cell clone was a necessary
step, although only loxP1 poses a serious threat of unintended loss.

The mouse expresses two FPGS isoforms; the P1 transcript was expressed only
in a few differentiated tissue, normally liver and kidney, whereas the P2 transcript was
expressed in normal and malignant dividing tissues. This dual promoter mechanism
directing expression of mouse isoforms is not conserved in humans. The human fpgs P2
transcript constitutes ~ 98% of fpgs transcripts in differentiated tissues and, as in the
mouse, everything in dividing cells (Turner and Moran. 2000). In this study, we
attempted to determine why the two promoter system is used in the mouse. Will the
deletion of the upstream P1 promoter activate or up-regulate the P2 transcription in
mouse liver and kidney? Is the two promoter system essential for mouse development?
Here, we report the deletion of fpgs P1 in vivo. We have generated a mouse that only
expresses P2 fpgs transcripts in all tissues, similar to the situation in humans. The
previous study of fpgs gene transcription in mouse tissues using RNAse protection
assays had demonstrated that the P2 transcript was present in most mouse dividing
tissues and the fpgs transcript found in mouse liver was almost exclusively transcribed
from the P1 promoter, with an estimated 3-5% of fpgs transcripts initiating from the
downstream promoter. In this work, we refine this estimate to <1%. Hence, two
100

possible outcomes were considered when we started this work; 1.) The deletion of P1
promoter and its exons may cause embryonic lethality, because the deletion of the
upstream promoter and exons may not be sufficient to activate the P2 promoter. 2.) The
deletion of P1 promoter and its exons may release the promoter interference previously
shown to operate in this gene (Racanelli et al. 2008), hence, activating the P2 promoter
enough that the P2 mRNA expression level will reach the level of that is expressed in
mouse dividing cells. To our surprise, homozygous P1 knockout mice are viable and
develop to adult mice and do not show any obvious impairments compared to wild type
littermates with respect to growth, weight, fertility and longevity. However, fpgs gene
expression from P2 in P1 knockout mouse liver demonstrated up-regulation of P2
transcription only by 4.6 fold compared to P2 expression in wild-type mouse. It was
surprising that the mice survived.
The previous study of chromatin immunoprecipitation mapping over the two
mouse fpgs promoters in our laboratory in different tissues had demonstrated that the
mouse fpgs gene used epigenetic marking of the P1 promoter and occlusion of the down
stream promoter to ensure the tissue specific usage of each of two fpgs isoforms
(Racanelli et al. 2008). In mouse liver, a promoter interference effect was found to
result from the activation of P1 in mouse liver which prevented the transcriptional
activation of P2. This effect appeared to be due to the residence of RNAPII elongation
complexes covering the nucleosome-deficient DNase hypersensitive region before P2,
hence, physically occluding initiation at the P2 promoter (Racanelli et al. 2008). The
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results of this study also suggest an interaction between the regulation of the two fpgs
gene promoters; deletion of upstream promoter P1 and exons A1a and A1b released the
apparent promoter interference mechanism and activated the downstream promoter. The
level of P2 fpgs transcription in homozygous P1 knockout mouse liver was found to be
15-100 folds lower than P1 transcription in liver of the wild type mouse. Despite the
low fpgs mRNA expression level in liver and kidney, the homozygous knockout mouse
shows no phenotypic alteration compared with its wild-type littermates and there were
no major developmental aberrations noted thus far. How do the homozygous knockout
mice survive under the circumstance of such a low level of fpgs gene expression in liver?
FPGS enzyme activity was measured in liver of knockout mice, heterozygous knockout
mice and wild-type mice. Interestingly, FPGS protein activity appeared to be reduced
30% in the heterozygous knockout and more than 50% reduced in homozygous
knockout compared to wild-type mice (Fig. 34), however, abundant enzyme activity
remained. These results may indicate that fpgs mRNA expression is not correlated
quantitatively to its protein expression in mouse liver, given that the P1 mRNA was
expressed in wild-type mice liver at a much higher level (100 fold) compared to P2
mRNA expressed in knockout mice liver. Compared with this 15-100-fold difference in
mRNA levels, FPGS enzyme activity in this tissue appeared to be only 2 fold lower
than those in the liver of P1 knockout mice than in wild type controls (Fig. 24, 41).
These differences may be caused by the artifacts in the enzyme assay. However,
alternative promoter usage resulting in alternative leader exons is known to affect the
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level of gene expression, the stability of the mRNA, the translational efficiency of the
mRNA, and affect the structure of the amino terminus of the protein encode by the gene
and consequence affect the protein stability (Torik. 1996). All these circumstances may
also be the explanation of unexpected FPGS enzyme activity in the knockout mouse
liver and the survival of homozygous knockout mice. These hypotheses remain to be
adequately tested. However, the survival of P1 knockout mice may also be the
consequence of the high folate content of the diet used in animal facility. A folate
depletion study is currently ongoing.
In summary, we have successfully generated a mouse reflected human folate
metabolism much closer than that in wild-type mice. It may become a useful tool for the
investigation of the function of human FPGS that plays a critical role in the folate
metabolism and anticancer therapeutics. The FPGS- humanized mouse liver model
would also be an appropriate in vivo tool for the study of the antifolate drug toxicity and
inhibition.
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APPENDIX A
Schematic diagram of pKO2lxFPGS-A1aA1b conditional KO targeting vector construction
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